U.S. patent application number 16/880933 was filed with the patent office on 2020-09-24 for method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives.
The applicant listed for this patent is BAYER PHARMA AKTIENGESELLSCHAFT. Invention is credited to Marie-Pierre COLLIN-KROEPELIN, Chantal FUERSTNER, Kersten GERICKE, Hans-Christian MILITZER, Thomas NEUBAUER, Philipp RUBENBAUER, Heiko SCHIRMER, Frank SUESSMEIER.
Application Number | 20200299271 16/880933 |
Document ID | / |
Family ID | 1000004869954 |
Filed Date | 2020-09-24 |
![](/patent/app/20200299271/US20200299271A1-20200924-C00001.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00002.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00003.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00004.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00005.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00006.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00007.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00008.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00009.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00010.png)
![](/patent/app/20200299271/US20200299271A1-20200924-C00011.png)
View All Diagrams
United States Patent
Application |
20200299271 |
Kind Code |
A1 |
SCHIRMER; Heiko ; et
al. |
September 24, 2020 |
METHOD FOR PRODUCING 5-HYDROXYALKYL-SUBSTITUTED 1-PHENYL-1,2,4-
TRIAZOLE DERIVATIVES
Abstract
The present application relates to a novel and improved process
for preparing 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole derivatives
of the formula (I) ##STR00001## in which R.sup.1A and R.sup.1B are
independently selected from the group consisting of hydrogen,
fluorine, chlorine, methyl, monofluoromethyl, difluoromethyl,
trifluoromethyl, ethyl, methoxy, difluoromethoxy and
trifluoromethoxy, to novel precursors for preparation thereof, and
to the preparation and use of the crystalline polymorph I of
(5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2-
,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihyd-
ro-3H-1,2,4-triazol-3-one of the formula (I-A-1).
Inventors: |
SCHIRMER; Heiko; (Solingen,
DE) ; RUBENBAUER; Philipp; (Bensheim, DE) ;
MILITZER; Hans-Christian; (Odenthal, DE) ;
COLLIN-KROEPELIN; Marie-Pierre; (Wuppertal, DE) ;
SUESSMEIER; Frank; (Muenchen, DE) ; GERICKE;
Kersten; (Wuppertal, DE) ; NEUBAUER; Thomas;
(Wuppertal, DE) ; FUERSTNER; Chantal;
(Muelheim/Ruhr, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
BAYER PHARMA AKTIENGESELLSCHAFT |
Berlin |
|
DE |
|
|
Family ID: |
1000004869954 |
Appl. No.: |
16/880933 |
Filed: |
May 21, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16098238 |
Nov 1, 2018 |
10703742 |
|
|
PCT/EP2017/060367 |
May 2, 2017 |
|
|
|
16880933 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 403/06 20130101;
C07D 249/12 20130101 |
International
Class: |
C07D 403/06 20060101
C07D403/06; C07D 249/12 20060101 C07D249/12 |
Foreign Application Data
Date |
Code |
Application Number |
May 3, 2016 |
EP |
16168163.0 |
May 3, 2016 |
EP |
16168165.5 |
May 3, 2016 |
EP |
16168166.3 |
May 3, 2016 |
EP |
16168169.7 |
May 3, 2016 |
EP |
16168172.1 |
Sep 3, 2017 |
EP |
17160086.9 |
Claims
1. A compound which is
(5-(4-Chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2-
,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihyd-
ro-3H-1,2,4-triazol-3-one of the formula (I-A-1) in crystalline
form of the polymorph I ##STR00062## wherein the x-ray
diffractogram of the compound exhibits peak maxima of the 2 theta
angle at 7.0, 8.9, 16.8, 17.7, 17.9, 18.1, 21.6, 21.8, 22.4 and
24.6.
2. A pharmaceutical composition comprising the crystalline form of
the polymorph I according to claim 1 of any other form of the
compound of the formula (I-A-1).
3. A pharmaceutical composition comprising the crystalline form of
the polymorph I according to claim 1 in more than 90% by weight
based on the total amount of the compound of the formula (I-A-1)
present.
4. A method for producing a pharmaceutical composition for
treatment of cardiovascular disorders or renal disorders, the
method comprising the step of mixing the crystalline form of the
polymorph I of claim 1 with at least one pharmaceutically
acceptable carrier.
5. A method of treating a cardiovascular disorder or a renal
disorder comprising administering an effective amount of a
crystalline form of the polymorph I according to claim 1.
6. A process for preparing the compound
(5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2-
,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihyd-
ro-3H-1,2,4-triazol-3-one of the formula (I-A-1) in crystalline
form of polymorph I, the process comprising stirring the compound
of the formula (I-A-1), in a mixture of methyl tert-butyl
ether/diisopropyl ether or of methyl tert-butyl ether/n-heptane at
a temperature of 20.degree. C. to 80.degree. C., wherein the
compounds is optionally present in one or more polymorphs or in
solvate form filtering the compound; washing the compound; drying
the compound under reduced pressure.
7. A compound of the general formula (X) ##STR00063##
8. A compound of the general formula (XI) ##STR00064## where
R.sup.2 is (C.sub.1-C.sub.4)-alkyl.
9. The compound of claim 8 wherein R.sup.2 is methyl.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Divisional application of U.S. patent
application Ser. No. 16/098,238, filed 1 Nov. 2018, which is a
National Stage entry of International Application No.
PCT/EP2017/060367, filed 2 May 2017, which claims priority to
European Patent Application No. 17160086.9, filed 9 Mar. 2017 and
European Patent Application Nos. 16168172.1, 16168169.7,
16168166.3, 16168165.5, and 16168163.0, all filed 3 May 2016. The
disclosure of the priority applications are incorporated in their
entirety herein by reference.
[0002] The present application relates to a novel and improved
process for preparing 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole
derivatives of the formula (I)
##STR00002##
in which [0003] R.sup.1A and R.sup.1B are independently selected
from the group consisting of hydrogen, fluorine, chlorine, methyl,
monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxy,
difluoromethoxy and trifluoromethoxy, to novel precursors for
preparation thereof, and to the preparation and use of the
crystalline polymorph I of
(5-(4-chlorophenyl)-2-({(1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,-
2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihy-
dro-3H-1,2,4-triazol-3-one of the formula (I-A-1).
[0004] Compounds of the formula (I) act as potent dual V1a/V2
receptor antagonists and can be used as agents for prophylaxis
and/or treatment of cardiovascular disorders and renal disorders,
for example acute and (worsening) chronic heart failure,
cardiorenal syndrome, hypervolaemic and euvolaemic hyponatraemia,
liver cirrhosis, ascites, oedemas and the syndrome of inappropriate
ADH secretion (SIADH), as disclosed in WO 2016/071212.
[0005] A general process for preparation of 5-phenyl-substituted
1,2,4-triazole derivatives is described in WO 2011/104322 (see
Scheme 8, Examples 21, 25, 54, 56-61 and 68-70 therein). By means
of the process described therein, however, it is not possible to
achieve 1,3,5 substitution of the 1,2,4-triazole ring and
especially 1-phenyl substitution of the 1,2,4-triazole ring in one
process step.
[0006] Scheme 1 below shows the process for preparing the
5-phenyl-substituted 1,2,4-triazole derivatives according to WO
2011/104322.
##STR00003##
[0007] Compounds of the formula (I) and the preparation thereof are
described in WO 2016/071212. The research synthesis described
therein is regarded as the closest prior art. Proceeding from
5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3-
H-1,2,4-triazol-3-one (II), the target compounds of the formula (I)
are prepared in 4 stages with an overall yield of not more than
.about.12% of theory. The diastereomers of the formula (I-A) and
(I-B) are obtained on the laboratory scale in a further stage from
the diastereomer mixture (I) via a chiral diastereomer separation.
The compounds of the formula (I) are obtained in solid form in WO
2016/071212, but there has been no description to date of a defined
crystallization process of the end stage for preparation of a
pharmaceutically usable crystal form.
[0008] Scheme 2 below shows the process for preparing the compounds
of the formula (I).
##STR00004## ##STR00005##
[0009] Up to and including step (V) to (VII), the synthesis
disclosed in WO 2016/071212 is analogous to the process disclosed
in WO 2011/104322.
[0010] For preparation of the compound of the formula (IV),
5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3-
H-1,2,4-triazol-3-one (II) is reacted with methyl bromoacetate
(III) to give methyl
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetate (IV). Subsequently, (IV) is
converted with hydrazine hydrate to
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}acetohydrazide (V). (V) is then
reacted with the imide compound (VI) to give the mixture of the
diastereomers
5-(4-chlorophenyl)-2-({5-[(1RS)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}met-
hyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-
-3-one (VII). A copper-catalysed aryl coupling ("Chan-Lam
coupling") of (VII) with a substituted phenylboronic acid (VIII)
leads to the substituted 5-(1-hydroxyethyl)-1-aryl-1,2,4-triazole
derivatives (I). Separation by chiral chromatography affords the
individual diastereomers
5-(4-chlorophenyl)-2-({5-[(1S)-1-hydroxyethyl]-1-(R.sup.1A,R.sup.1B)-phen-
yl-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]--
2,4-dihydro-3H-1,2,4-triazol-3-one (I-A) and
5-(4-chlorophenyl)-2-({5-[(1R)-1-hydroxyethyl]-1-(R.sup.1A,R.sup.1B)-phen-
yl-H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2-
,4-dihydro-3H-1,2,4-triazol-3-one (I-B).
[0011] The reaction scheme outlined above is described in WO
2016/071212 as follows: The reaction sequence from a compound of
the formula (II) via the compounds of the formulae (IV), (V) and
(VII) to compounds of the formula (I) and the separation into the
diastereomers (I-A) and (I-B); see Scheme 2 and Examples 1A, 2A, 4A
and 10 to 83 therein.
[0012] However, this process which is known from WO 2016/071212 has
various disadvantages in the reaction regime which have a
particularly unfavourable effect in the preparation of the
compounds of the formula (I) on the industrial scale. The overall
yield over the four stages (II) to (I) is very low at less than 15%
of theory (about 1.3% to 13.1%). Many steps proceed in very high
dilution and with very high reagent excesses.
[0013] A particularly disadvantageous aspect of the synthesis
described in WO 2016/071212 is found to be the synthesis steps
(VII) to (I) (copper-mediated aryl coupling, "Chan-Lam coupling"),
which proceeds only with a maximum isolated yield of 30% (between
3.0% and 30.1%) and is thus disadvantageous from an atom economy
point of view. Another disadvantage is that the reaction can give
rise to regioisomeric phenyltriazole derivatives via a coupling
reaction to another ring nitrogen atom (ring tautomerism of the
1,2,4-triazole derivatives (VII)). This likewise has an adverse
effect on the yield in this step; in addition, the regioisomeric
products then have to be removed in a complex manner in an
additional purification step. Furthermore, this reaction step is
particularly disadvantageous for a synthesis on the industrial
scale, since stoichiometric amounts of copper acetate are used in
this reaction. This is disadvantageous since the remaining amounts
of copper salt have to be removed down to below the maximum limit
permissible in the product for regulatory reasons, which means
additional cost and inconvenience. Moreover, the reagents should be
obtainable in a simple and inexpensive manner.
[0014] In the synthesis according to WO 2016/071212, the
stereoisomeric mixture of the formula (I) was separated into the
diastereomers on the laboratory scale by means of chiral
chromatography. Such a chromatographic separation is very costly
and time-consuming and therefore disadvantageous for a synthesis on
the industrial scale. Furthermore, this additional stage further
reduces the overall yield. A further disadvantage is that the
target compound, by the method described in WO 2016/071212, is not
obtained in a pharmaceutically usable defined crystal form.
[0015] There was therefore a need for a synthesis practicable on
the industrial scale that affords the compounds of the formula (I)
reproducibly in a high overall yield, with low production costs and
high purity. There was additionally a need for a synthesis which is
practicable on the industrial scale and meets all regulatory
demands that are to be complied with for use of the active
ingredient in clinical trials and can be used for later regulatory
submission.
[0016] Surprisingly, a very efficient process for preparation of
the compound of the formula (I) has now been found, which meets the
demands mentioned above. The novel process enables an efficient
synthesis of 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole
derivatives.
[0017] An important advantage of the process according to the
invention is the distinct increase in yield over all stages. The
novel process according to the invention as per process variant (A)
affords the target compounds (I) in four stages in an overall yield
of more than 20% of theory (between 23.8% and 53.2%).
Chromatographic purification of intermediates is unnecessary. Thus,
the final two stages in an alternative process variant (B) and even
the final three stages in a further alternative process variant (C)
can be conducted as a one-pot method. In this way, it is possible
to achieve a further increase in the overall yield over four stages
(up to 63.2%).
[0018] The schemes and process steps which are described
hereinafter are synthesis routes to the inventive compounds of the
general formula (I) and should not be regarded as a restriction.
The person skilled in the art will be aware that the sequence of
transformations as shown by way of example in Schemes 3 and 4 can
be modified in various ways, and the sequence presented should
therefore not be regarded as a restriction. In addition, it is
possible to convert functional groups of individual radicals and
substituents, especially those listed under R.sup.1 and R.sup.2,
before and/or after the transformations described by way of
example, proceeding from other compounds of the formula (I) or
precursors thereof obtained by the above processes. These
transformations are conducted by customary methods familiar to the
person skilled in the art and include, for example, reactions such
as nucleophilic or electrophilic substitution reactions,
transition-metal-mediated coupling reactions, preparation and
addition reactions of metal organyls (e.g. Grignard compounds or
lithium organyls), oxidation and reduction reactions,
hydrogenation, halogenation (e.g. fluorination, bromination),
dehalogenation, amination, alkylation and acylation, the formation
of carboxylic esters, carboxamides and sulphonamides, ester
cleavage and hydrolysis, and the introduction and removal of
temporary protecting groups or other reactions known to those
skilled in the art. These conversions also include those wherein a
functionality is introduced, which enables further conversion of
substituents. Suitable protecting groups and reagents and reaction
conditions for the introduction and detachment thereof are known to
those skilled in the art (see, for example, T. W. Greene and P. G.
M. Wuts; "Protective Groups in Organic Synthesis", 3rd Edition,
Wiley 1999). Specific examples are cited in the text passages which
follow.
[0019] Scheme 3 below illustrates the novel process according to
the invention for preparing the compounds of the formula (I).
##STR00006##
[0020] Where, in the compounds of Synthesis Scheme 3, [0021]
R.sup.1A and R.sup.1B are independently selected from the group
consisting of hydrogen, fluorine, chlorine, methyl,
monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxy,
difluoromethoxy and trifluoromethoxy.
[0022] Where, preferably, in the compounds of Synthesis Scheme 3,
[0023] R.sup.1A and R.sup.1B are independently selected from the
group consisting of hydrogen, fluorine and chlorine, where at least
one of the substituents is not hydrogen.
[0024] Where, more preferably, in the compounds of Synthesis Scheme
3, [0025] R.sup.1A is hydrogen, and [0026] R.sup.1B is chlorine in
the 2 position or in the 3 position.
[0027] Where, most preferably, in the compounds of Synthesis Scheme
3, [0028] R.sup.1A is hydrogen, and [0029] R.sup.1B is chlorine in
the 3 position.
[0030] There follows a discussion of the individual stages of the
process according to the invention for preparing the compound of
the formula (I) according to Scheme 3. There is likewise discussion
of alternatives which are characterized by the non-isolation of the
compounds of the formula (XI) and (XIV).
[0031] For preparation of 5-(1-hydroxyethyl)-1-aryl-1,2,4-triazole
derivatives (I),
5-(4-chlorophenyl)-4-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-2,4-dihydro-3-
H-1,2,4-triazol-3-one (II) is converted to
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetonitrile (X) (Step 1).
Subsequently, the nitrile compound (X) is converted by reaction
with sodium methoxide to methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropy-
l]-4,5-dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) (Step 2).
The 1,2,4-triazole ring is then formed via a three-component
cyclization reaction, wherein the imino ester compound (XI) reacts
with 2-acetoxypropionyl chloride (XII) and a substituted
phenylhydrazine compound (XIII), and the
1-{3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]--
4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[(R.sup.1A,R.sup.1B)-phenyl]-1-
H-1,2,4-triazol-5-yl}ethyl acetate (XIV) is obtained (Step 3). The
subsequent detachment of the acetyl group affords the target
compounds of the formula (I) (Step 4). In one variant (B), the
process can be conducted in such a way that the protected acetate
(XIV) is not isolated, but directly converted further in solution
(Steps 3+4). In a further variant (C), the process can be conducted
as a one-pot method via the stages
(X).fwdarw.(XI).fwdarw.(XIV).fwdarw.(I) (Steps 2+3+4); in this
case, the overall process consists only of 2 isolated stages rather
than 4 stages in the prior art.
[0032] An especially advantageous feature is the three-component
cyclization reaction according to the invention for formation of
the 1,2,4-triazole ring (Step 3), which enables introduction of the
two ring substituents in the 1 and 5 positions in one process step,
such that a high yield is achieved for this step (37.0% to 83.0%
for Step 3; after protecting group attachment: 36.7% to 82.2% over
2 stages for Steps 3+4). The synthesis described in the prior art
(Scheme 2) gives a significantly lower yield over two stages of
2.9% to 28.9% via the analogous sequence
(V).fwdarw.(VII).fwdarw.(I).
[0033] A further advantageous feature is also the robustness of the
process according to the invention, such that, as described above,
the sequence can also be executed as a one-pot method (process
variants B and C), such that the intermediates need not be isolated
and, rather than being purified by chromatography, the
intermediates are subjected directly to a subsequent step in the
same reaction vessel and/or reaction medium. Such a one-pot method
is especially advantageous for an industrial scale synthesis, since
it is possible in this way to avoid additional workup steps, and a
high overall yield for the process is achieved.
[0034] The starting compound of the formula (II) described in
Synthesis Scheme 3 can be prepared according to Synthesis Scheme 4
below, proceeding from starting compounds that are commercially
available or known to the person skilled in the art:
##STR00007##
[0035] The starting substances of the formula (II) are described in
WO 2010/105770 (see Schemes 4 and 5; Examples 1A, 2A, 3A, 4A and
158A therein) and WO 2011/104322 (see Scheme 1; Examples 1A, 2A,
3A, 4A and 5A therein). The compounds of the formula (II) are
obtained by reacting 4-chlorobenzohydrazide (XV) with ethyl
2-isocyanatoacetate (XVI) to give ethyl
N-({2-[(4-chlorophenyl)carbonyl]hydrazinyl}carbonyl)glycinate
(XVI). The latter is then converted by a base-induced cyclization
reaction to
[3-(4-chlorophenyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetic
acid (XVIII).
5-(4-Chlorophenyl)-4-(3,3,3-trifluoro-2-oxopropyl)-2,4-dihydro-3-
H-1,2,4-triazol-3-one (IX) is then obtained by reaction with
trifluoroacetic anhydride and subsequent treatment with
hydrochloric acid. The ketone (IX) is then converted by an
asymmetric transfer hydrogenation by means of an enantioselective
ruthenium(II) catalyst to the chiral alcohol (II).
[0036] With the novel inventive synthesis, it has been possible to
prepare the target compound (I) in a very efficient manner. The
process offers considerable advantages over the prior art with
regard to scalability and industrial implementation. The overall
yield is significantly higher compared to published data; moreover,
a very high purity of the active ingredient is generally achieved.
One embodiment of the novel process enables the reproducible,
economic preparation of the defined crystal form that has not been
described before in the prior art. By the inventive process
presented here, several kg of material for clinical trials have
already been successfully produced.
[0037] Preferred salts in the context of the present invention are
physiologically acceptable salts of the compounds according to the
invention (for example, cf. S. M. Berge et al., "Pharmaceutical
Salts", J. Pharm. Sci. 1977, 66, 1-19). However, the invention also
encompasses salts which themselves are unsuitable for
pharmaceutical applications but which can be used, for example, for
the isolation or purification of the compounds according to the
invention.
[0038] Physiologically acceptable salts of the compounds according
to the invention include acid addition salts of mineral acids,
carboxylic acids and sulphonic acids, for example salts of
hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric
acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic
acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic
acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric
acid, malic acid, citric acid, fumaric acid, maleic acid and
benzoic acid.
[0039] Physiologically acceptable salts of the inventive compounds
also include salts of customary bases, preferred examples being
alkali metal salts (e.g. sodium salts and potassium salts),
alkaline earth metal salts (e.g. calcium salts and magnesium salts)
and ammonium salts, derived from ammonia or organic amines having 1
to 16 carbon atoms, preferred examples being ethylamine,
diethylamine, triethylamine, ethyldiisopropylamine,
monoethanolamine, diethanolamine, triethanolamine,
dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine,
N-methylmorpholine, arginine, lysine, ethylenediamine,
N-methylpiperidine and choline.
[0040] Solvates in the context of the invention are described as
those forms of the compounds according to the invention which form
a complex in the solid or liquid state by coordination with solvent
molecules. Hydrates are a specific form of the solvates in which
the coordination is with water.
[0041] The compounds of the formula (I-A), (XII-A), (XIV-A) and
(I-B), (XII-B), (XIV-B) are each a subset of the compounds of the
formula (I), (XII) and (XIV) and are each the enantiomers or
diastereomers with regard to the stereocentre of the alcohol group
in the 5 position of the 1,2,4-triazole ring, or of the protected
form thereof. The compounds of the formula (I-A), (XII-A) and
(XIV-A) are assigned here to an (S) configuration of the
stereocentre, and the compounds of the formula (I-B), (XII-B) and
(XIV-A) are each assigned to an (R) configuration of the
stereocentre.
[0042] If the compounds according to the invention can occur in
tautomeric forms, the present invention encompasses all the
tautomeric forms.
[0043] The following three tautomer representations (a), (b) and
(c) of a triazole derivative are equivalent to one another and
synonymous and in all cases are descriptive of a 1,4-disubstituted
triazole derivative.
##STR00008##
[0044] This applies especially to the following structural
elements: 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl,
4H-1,2,4-triazol-3-yl and 4H-1,2,4-triazol-5-yl. Y.sup.1 and
Y.sup.2 here are different substituents.
[0045] The present invention provides a process for preparing the
compounds of the general formula (I), or the salts thereof, the
solvates thereof or the solvates of the salts thereof,
characterized in that it comprises steps [C] and [D], wherein
[0046] [C] a compound of the general formula (XI)
##STR00009## [0047] where [0048] R.sup.2 is
(C.sub.1-C.sub.4)-alkyl, preferably methyl. in a successive manner,
is reacted in a first step
[0049] [C-1] in the presence of a base with an acid chloride of the
general formula (XII)
##STR00010## [0050] where [0051] PG is a protecting group,
preferably acetyl, and the resultant intermediate is then reacted
in a subsequent step
[0052] [C-2] in the presence of a base with a phenylhydrazine
compound of the general formula (XIII)
##STR00011## [0053] where R.sup.1A and R.sup.1B are independently
selected from the group consisting of hydrogen, fluorine, chlorine,
methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl,
methoxy, difluoromethoxy and trifluoromethoxy to give a
1,2,4-triazolyl compound of the general formula (XIV)
[0053] ##STR00012## [0054] where PG, R.sup.1A and R.sup.1B have the
definitions given above and the latter is converted in a subsequent
step
[0055] [D] by detachment of the protecting group PG to a compound
of the general formula (I)
##STR00013## [0056] where R.sup.1A and R.sup.iB have the
definitions given above.
[0057] By contrast with the prior art (WO 2016/071212), the
preparation of (I) (via (XI)+(XII)+(XIII).fwdarw.(XIV).fwdarw.(I),
see Scheme 3: steps 3+4: 36.7% to 82.2% over 2 stages) proceeds
with a much higher yield than for an analogous sequence in the
prior art (see Scheme 2: (V).fwdarw.(VII).fwdarw.(I), 2.9% to 28.9%
over 2 stages).
[0058] In an advantageous embodiment, the process according to the
invention is conducted as a one-pot reaction in a multistage mode
of operation adapted to the chemical mechanism.
[0059] In this context, the process is conducted in the presence of
a suitable solvent and the intermediate that results from step
[C-1] is then converted without isolation, i.e. in solution, in the
subsequent step [C-2].
[0060] In a further advantageous embodiment, the 1,2,4-triazolyl
compound of the general formula (XIV) obtained from step [C-2] is
converted without isolation, i.e. in solution, to a compound of the
general formula (I) in the subsequent step [D].
[0061] In one embodiment, the process according to the invention,
prior to step [C], comprises a further step [B] wherein
[0062] [B] a compound of the formula (X)
##STR00014##
is reacted with a basic (C.sub.1-C.sub.4)-alkoxylate, preferably
sodium methoxide, to give an imino ester compound of the general
formula (XI)
##STR00015## [0063] where [0064] R.sup.2 is
(C.sub.1-C.sub.4)-alkyl, preferably methyl.
[0065] In an advantageous embodiment, the process according to the
invention is conducted as a one-pot reaction in a multistage mode
of operation adapted to the chemical mechanism.
[0066] In this context, the reaction is conducted in the presence
of a suitable solvent and the imino ester compound of the general
formula (XI) that results from step [B] is then converted without
isolation, i.e. in solution, in a subsequent step [C].
[0067] In one embodiment, the process according to the invention
comprises, prior to step [C], a step [B] and, prior to step [B], a
further step [A], wherein
[0068] [A] a compound of the general formula (II)
##STR00016##
is reacted with a nitrile compound (IX)
##STR00017## [0069] where X is a leaving group, preferably chloride
or bromide, to give a compound of the general formula (X)
##STR00018##
[0070] In a further embodiment of the process according to the
invention, this process comprises steps [A], [B], [C] and [D],
wherein
[0071] [A] a compound of the general formula (II)
##STR00019##
is reacted with a nitrile compound (IX)
##STR00020## [0072] where X is a leaving group, preferably chloride
or bromide, to give a compound of the general formula (X)
##STR00021##
[0072] and the latter is reacted in a subsequent step
[0073] [B] with a basic (C.sub.1-C.sub.4)-alkoxylate, preferably
sodium methoxide, to give an imino ester compound of the general
formula (XI)
##STR00022## [0074] where [0075] R.sup.2 is
(C.sub.1-C.sub.4)-alkyl, preferably methyl. and the latter is
reacted in a subsequent step
[0076] [C] in a successive manner, in a first step
[0077] [C-1] in the presence of a base with an acid chloride of the
general formula (XII)
##STR00023## [0078] where [0079] PG is a protecting group,
preferably acetyl, and the resultant intermediate is then reacted
in a subsequent step
[0080] [C-2] in the presence of a base with a phenylhydrazine
compound of the general formula (XIII)
##STR00024## [0081] where R.sup.1A and R.sup.1B are independently
selected from the group consisting of hydrogen, fluorine, chlorine,
methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl,
methoxy, difluoromethoxy and trifluoromethoxy to give a
1,2,4-triazolyl compound of the general formula (XIV)
[0081] ##STR00025## [0082] where R.sup.1A and R.sup.1B have the
definitions given above, and [0083] PG is a protecting group,
preferably acetyl, and the latter is reacted in a subsequent
step
[0084] [D] by detachment of the protecting group PG to give a
compound of the general formula (I)
##STR00026## [0085] where R.sup.1A and R.sup.1B have the
definitions given above.
[0086] Preference is given to a process for preparing compounds of
the formula (I), characterized in that R.sup.1A and R.sup.1B are
independently selected from the group consisting of hydrogen,
fluorine and chlorine, where at least one of the substituents is
not hydrogen.
[0087] Particular preference is given to a process for preparing
compounds of the formula (I), characterized in that R.sup.1A is
hydrogen and R.sup.1B is chlorine in the 2 position or in the 3
position.
[0088] Very particular preference is given to a process for
preparing compounds of the formula (I), characterized in that
R.sup.1A is hydrogen and R.sup.1B is chlorine in the 3
position.
[0089] Very particular preference is given to a process for
preparing compounds of the formula (I-A-1)
##STR00027##
[0090] The present invention further provides a process for
preparing the compounds of the general formula (X), or the salts
thereof, the solvates thereof or the solvates of the salts thereof,
characterized in that it comprises a step [A], wherein
[0091] [A] a compound of the general formula (II)
##STR00028##
is reacted with a nitrile compound (IX)
##STR00029## [0092] where X is a leaving group, preferably chloride
or bromide, to give a compound of the general formula (X)
##STR00030##
[0093] The present invention further provides a process for
preparing the compounds of the general formula (XI), or the salts
thereof, the solvates thereof or the solvates of the salts thereof,
characterized in that it comprises a step [B], wherein
[0094] [B] a compound of the formula (X)
##STR00031##
is reacted with a basic (C.sub.1-C.sub.4)-alkoxylate, preferably
sodium methoxide, to give an imino ester compound of the general
formula (XI)
##STR00032## [0095] where [0096] R.sup.2 is
(C.sub.1-C.sub.4)-alkyl, preferably methyl.
[0097] The present invention further provides a compound of the
general formula (X)
##STR00033##
[0098] In a preferred embodiment of the present invention, the
compound is
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetonitrile (X-a)
##STR00034##
[0099] The present invention further provides for the use of a
compound of the general formula (X) for preparation of a compound
of the general formula (I).
[0100] The present invention further provides a compound of the
general formula (XI)
##STR00035## [0101] where [0102] R.sup.2 is
(C.sub.1-C.sub.4)-alkyl, preferably methyl.
[0103] In a preferred embodiment of the present invention, the
compound is methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropy-
l]-4,5-dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI-a)
##STR00036##
[0104] The present invention further provides for the use of a
compound of the general formula (XI) for preparation of a compound
of the general formula (I).
[0105] The present invention further provides for the use of a
compound of the general formula (XIV) for preparation of a compound
of the general formula (I).
[0106] Step 1:
[0107] Suitable bases for process step [A]: (II)+(IX).fwdarw.(X)
are the standard inorganic or organic bases, for example and with
preference alkali metal carbonates such as sodium carbonate,
potassium carbonate or caesium carbonate, alkali metal alkoxides
such as sodium tert-butoxide or potassium tert-butoxide, or organic
amines such as N,N-diisopropylethylamine (DIPEA) and triethylamine.
Solvents used may be inert solvents, for example acetonitrile,
methyl isobutyl ketone, dioxane, dimethylformamide,
dimethylacetamide, N-methylpyrrolidinone, dimethyl sulphoxide or
sulpholane. Preference is given to using potassium carbonate in
methyl isobutyl ketone or acetonitrile.
[0108] If appropriate, these process steps can advantageously be
conducted with addition of alkylation catalysts, for example
lithium bromide, sodium iodide, tetra-n-butylammonium bromide or
benzyltriethylammonium chloride. In addition, it may be found to be
advantageous to meter in the chloroacetonitrile or
bromoacetonitrile alkylating agent over a prolonged period. The
reactions are effected generally within a temperature range from
+40.degree. C. to +120.degree. C., preferably at +60.degree. C. to
+80.degree. C.
[0109] The reaction can be performed at standard, elevated or
reduced pressure (e.g. from 0.5 to 5 bar); in general, standard
pressure is employed.
[0110] The compounds of the formula (X) may alternatively also be
prepared from compounds of the formula (XX) that are known from the
literature (see Scheme 5):
##STR00037##
[0111] The coupling reaction (XX).fwdarw.(XXI) [amide formation]
can be effected either by a direct route with the aid of a
condensing or activating agent in the presence of a base or via the
intermediate stage of a carbonyl chloride, carboxylic ester or
carbonyl imidazolide obtainable from (XX).
[0112] Suitable condensing or activating agents of this kind are,
for example, carbodiimides such as N,N'-diethyl-, N,N'-dipropyl-,
N,N'-diisopropyl-, N,N'-dicyclohexylcarbodiimide (DCC) or
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC),
phosgene derivatives such as N,N'-carbonyldiimidazole (CDI),
isopropyl chloroformate or isobutyl chloroformate, 1,2-oxazolium
compounds such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulphate or
2-tert-butyl-5-methylisoxazolium perchlorate, acylamino compounds
such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline,
.alpha.-chloroenamines such as
1-chloro-N,N,2-trimethylprop-1-en-1-amine, 1,3,5-triazine
derivatives such as
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride,
phosphorus compounds such as n-propanephosphonic anhydride (T3P,
PPACA), diethyl cyanophosphonate, diphenylphosphoryl azide (DPPA),
bis(2-oxo-3-oxazolidinyl)phosphoryl chloride,
benzotriazol-1-yloxytris(dimethylamino)phosphonium
hexafluorophosphate or
benzotriazol-1-yloxytris(pyrrolidino)phosphonium
hexafluorophosphate (PyBOP), or uronium compounds such as
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (TBTU),
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HBTU),
O-(1H-6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TCTU),
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU) or
2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TPTU), optionally in combination with further
auxiliaries such as 1-hydroxybenzotriazole (HOBt) or
N-hydroxysuccinimide (HOSu), and suitable bases are alkali metal
carbonates, e.g. sodium or potassium carbonate, or tertiary amine
bases such as triethylamine, N-methylmorpholine (NMM),
N-methylpiperidine (NMP), N,N-diisopropylethylamine (DIPEA),
pyridine or 4-N,N-dimethylaminopyridine (DMAP). Typically, the acid
chlorides are prepared by reaction with thionyl chloride or oxalyl
chloride in an inert solvent such as dichloromethane or
N,N-dimethylformamide. It is likewise possible to use mixtures of
the solvents listed.
[0113] The conversion to the nitrile (XXI).fwdarw.(X) can be
conducted in the presence of a dehydrating agent. Typical
dehydrating agents are, for example, trifluoroacetic anhydride
(TFAA), phosphorus pentoxide (P.sub.4O.sub.10), phosphoryl chloride
(POCl.sub.3), phosphorus pentachloride (PCl.sub.5),
CCl.sub.4--PPh.sub.3 (Appel's reagent), hexamethylphosphoramide
(HMPA); methyl N-(triethylammoniumsulphonyl)carbamate (Burgess
reagent), (chloromethylene)dimethyliminium chloride (Vilsmeier
reagent), oxalyl chloride/DMSO and thionyl chloride
(SOCl.sub.2).
[0114] Typical solvents for the two process steps (XX).fwdarw.(XXI)
and (XXI).fwdarw.(X) are, for example, ethers such as diethyl
ether, dioxane, tetrahydrofuran, glycol dimethyl ether or
diethylene glycol dimethyl ether, hydrocarbons such as benzene,
toluene, xylene, hexane, cyclohexane or mineral oil fractions,
halohydrocarbons such as dichloromethane, trichloromethane,
tetrachloromethane, 1,2-dichloroethane, trichloroethylene or
chlorobenzene, or other solvents such as acetone, ethyl acetate,
acetonitrile, dimethyl sulphoxide, N,N-dimethylformamide,
N,N'-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP) or
pyridine. It is equally possible to use mixtures of the solvents
mentioned.
[0115] Typically and with preference, the carboxylic acid (XX) is
reacted in a first step with pivaloyl chloride in the presence of
pyridine, giving an intermediate which is reacted with ammonia in a
subsequent step. Typically, the intermediate formed is not isolated
and the reaction is conducted as a one-pot reaction over the two
stages. Suitable bases for the first step are preferably pyridine,
4-(N,N-dimethylamino)pyridine or N,N-diisopropylethylamine (DIPEA).
The conversion of carboxamide (XX) to the nitrile (X) is then
typically effected via the reaction with trifluoroacetic anhydride.
Both reactions are conducted in an inert organic solvent,
preferably tetrahydrofuran.
[0116] Compounds of the formula (XX) are known from the literature
(see WO 2010/105770, Scheme 2, Examples 8A and 9A; and WO
2011/104322, Scheme 11).
[0117] Step 2:
[0118] Bases which can be used for the preparation of the imino
ester (XI) in process step [B] are basic (C.sub.1-C.sub.4)-alkali
metal alkoxides, for example sodium methoxide, sodium ethoxide,
sodium propoxide, sodium isopropoxide, sodium tert-butoxide or
potassium tert-butoxide. Suitable alcohols are alcohols such as
methanol, ethanol, n-propanal, 2-propanal, n-butanol, 2-butanol and
tert-butanol. Preference is given to using sodium methoxide in
methanol.
[0119] The reactions are generally effected within a temperature
range from +20 to +80.degree. C., preferably from +40 to
+60.degree. C. The imino ester (XI) need not be intermediately
isolated, but can be used directly in the subsequent stage by
distilling methanol off and changing the solvent to toluene or
tetrahydrofuran.
[0120] Step 3:
[0121] The multicomponent cyclization reaction in process step [C]
is effected in a two-stage process. First of all, in process step
[C-1], the imino ester (XI) is reacted with the acid chloride (XII)
in the presence of a base and the resultant intermediate is then
reacted with the phenylhydrazine compound (XIII) in the presence of
a base in process step [C-2]. Typically, the intermediate formed is
not isolated and the two-stage process is conducted as a one-pot
reaction.
[0122] Advantageously, the acid chloride (XII) is used here in step
[C-1] in an amount of 1.1 to 1.5 mol, preferably in an amount of
1.2 mol, based on 1 mol of the compound of the formula (XI). The
base is typically used in step [C-1] in an amount of 1 to 2.5 mol,
preferably in an amount of 1.05 to 2.0 mol, more preferably in an
amount of 1.05 to 1.5 mol, based on 1 mol of the compound of the
formula (XII).
[0123] The hydrazine (XIII) in step [C-2] can also be used in salt
form, for example as the hydrochloride or as the p-toluenesulphonic
salt (tosylate). Under the basic reaction conditions, the salt form
is then converted to the free hydrazine. The amount of base can be
adjusted correspondingly in this case. In a further advantageous
embodiment, the hydrazine salt is neutralized prior to addition in
a separate reaction vessel and the resulting solution is then added
to the reaction mixture as a solution, optionally after removal of
the salt formed by filtration.
[0124] The base is typically used in step [C-2] in an amount of
1.05 to 1.5 mol, preferably in an amount of 1.2 to 1.5 mol, based
on 1 mol of the compound of the formula (XIII).
[0125] Suitable bases for the two steps are typically tertiary
amine bases, for example N,N-diisopropylethylamine (DIPEA),
triethylamine, triisopropylamine, N-methylimidazole,
N-methylmorpholine, pyridine and 4-(dimethylamino)pyridine.
Preference is given to triethylamine or N,N-diisopropylethylamine.
Particular preference is given to diisopropylethylamine.
[0126] Suitable solvents are inert organic solvents, for example
dichloromethane, 1,2-dichloroethane, methyl tert-butyl ether,
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxymethane, toluene,
pyridine, ethyl acetate, acetonitrile or N,N-dimethylformamide or
mixtures of these solvents.
[0127] Preference is given to using tetrahydrofuran (THF) or
mixtures of tetrahydrofuran and toluene.
[0128] The reaction with the acid chloride (XII) in step [C-1] and
with the hydrazine (XIII) in step [C-2] is effected within a
temperature range from -20.degree. C. to +30.degree. C., preferably
from 0.degree. C. to +10.degree. C. For triazole formation with
elimination of water (cyclization) in step [C-2], the reaction
mixture is subsequently brought to a temperature of +20 to
+150.degree. C. Preferably, the reaction is conducted at a
temperature of +70 to +80.degree. C.
[0129] Step 4: The introduction and detachment of the protecting
group PG in process step [D] is effected by standard literature
methods [see, for example, T. W. Greene and P. G. M. Wuts,
Protective Groups in Organic Synthesis, Wiley, New York, 1999]. For
instance, the acetyl group is preferably removed with a base, for
example aqueous sodium hydroxide solution.
[0130] When the protecting group detachment in process step [D] is
conducted with aqueous sodium hydroxide solution, the workup is
effected, for example, by extraction with a suitable solvent,
followed by repeated washing and drying. Preference is given to
extraction with methyl tert-butyl ether (MtBE).
[0131] The compounds of the formulae (II), (IX), (XII), (XIII) and
(XX) are either commercially available or described as such in the
literature, or they can be prepared in a way obvious to the person
skilled in the art, in analogy to methods published in the
literature. Numerous detailed methods and literature information
for preparation of the starting materials can also be found in the
Experimental.
[0132] Since the compound of the formula (I-A-1) is being developed
in the form of a tablet, there is a high demand for reproducible
isolation of the isolated compound of the formula (I-A-1) in a
defined crystalline form, such that reproducible bioavailability
can be assured.
[0133] It has been found that, surprisingly, the compound
(5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1
S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl
J}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-t-
riazol-3-one of the formula (I-A-1)
##STR00038##
can crystallize out of a mixture of methyl tert-butyl
ether/diisopropyl ether or out of a mixture of methyl tert-butyl
ether/n-heptane, with reproducible formation of crystalline
polymorph I (Step 5).
[0134] Step 5:
[0135] A solution of the compound of the formula (I-A-1) in a 5- to
10-fold excess of methyl tert-butyl ether (MtBE) is stirred here at
20 to 80.degree. C., preferably at 50 to 60.degree. C. and more
preferably at reflux temperature of the methyl tert-butyl ether
(about 54.degree. C.), and admixed with diisopropyl ether at this
temperature. With continued addition of diisopropyl ether, MtBE is
distilled off. In the course of this, the compound of the formula
(I-A-1) crystallizes out. The system is cooled to a temperature of
0 to 30.degree. C., preferably 10 to 20.degree. C., and the
crystals are isolated and dried under reduced pressure at 40 to
60.degree. C., preferably at 40 to 50.degree. C.
[0136] Alternatively, it is also possible to use a mixture of
methyl tert-butyl ether/n-heptane. Here, a solution of the compound
of the formula (I-A-1) in a 5- to 10-fold excess of methyl
tert-butyl ether (MtBE) is stirred at 20 to 80.degree. C.,
preferably at 50 to 60.degree. C. and more preferably at reflux
temperature of the methyl tert-butyl ether (about 54.degree. C.),
and admixed with 1.5 to 2.5 times the volume of n-heptane at this
temperature, and the compound of the formula (I-A-1) crystallizes
out. The system is cooled to a temperature of 0 to 30.degree. C.,
preferably 10 to 20.degree. C., and the crystals are isolated and
dried under reduced pressure at 40 to 80.degree. C., preferably at
40 to 50.degree. C.
[0137] For GMP-related reasons, it may be advisable to subject the
product solution in MtBE first to a particle filtration prior to
the heating.
[0138] The workup is generally effected by filtration, repeated
washing with diisopropyl ether or n-heptane, and subsequent
drying.
[0139] The achieved chemical purity of >99% and the content of
about 100% meet the criteria for commercial products according to
ICH guidelines. The optical purity is >>99% e.e.
[0140] The crystallization process is very robust and delivers the
desired crystal form in a reproducible manner. The compound of the
formula (I) is generally micronized and formulated pharmaceutically
to tablets. It has been found that the crystal form has very good
stability properties (even at high humidity) and can be stored
without loss of stability over several months.
[0141] The present invention further provides the compound
(5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2-
,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihyd-
ro-3H-1,2,4-triazol-3-one of the formula (I-A-1) in crystalline
form of polymorph I.
[0142] The present invention provides the compound of the formula
(I-A-1) in crystalline form of polymorph I, characterized in that
the x-ray diffractogram of the compound has peak maxima of the 2
theta angle at 7.0, 8.9, 16.8, 17.7, 17.9, 18.1, 21.6, 21.8, 22.4
and 24.6.
[0143] The present invention further provides a process for
preparing the compound of the formula (I-A-1) in crystalline form
of polymorph I, characterized in that the compound of the formula
(I-A-1), present in one or more polymorphs or in solvate form, is
stirred in a mixture of methyl tert-butyl ether/diisopropyl ether
or of methyl tert-butyl ether/n-heptane at a temperature of
20.degree. C. to 80.degree. C., then filtered, washed and dried
under reduced pressure.
[0144] A preferred solvent for the process for preparing the
compounds of the formula (I-A-1) in crystalline form of polymorph I
is a mixture of methyl tert-butyl ether/diisopropyl ether or a
mixture of methyl tert-butyl ether/n-heptane.
[0145] A preferred temperature range for the process for preparing
the compound of the formula (I-A-1) in crystalline form of
polymorph I is at the reflux temperature of methyl tert-butyl ether
(at about 54.degree. C.).
[0146] The present invention further provides the compound of the
formula (I-A-1) in crystalline form of polymorph I as described
above for treatment of disorders.
[0147] The present invention further provides a medicament
comprising a compound of the formula (I-A-1) in crystalline form of
polymorph I as described above and no major proportions of any
other form of the compound of the formula (I-A-1) than the
crystalline form of polymorph I as described above. The present
invention further provides a medicament comprising a compound of
the formula (I-A-1) in crystalline form of polymorph I as described
above in more than 90 percent by weight based on the total amount
of the compound of the formula (I-A-1) present.
[0148] The present invention further provides for the use of the
compound of the formula (I-A-1) in crystalline form of polymorph I
as described above for production of a medicament for treatment of
cardiovascular disorders and renal disorders.
[0149] The present invention further provides the method for
treatment of cardiovascular disorders and renal disorders by
administering an effective amount of a compound of the formula
(I-A-1) in crystalline form of polymorph I as described above.
[0150] The inventive compounds of the formula (I-A-1) act as potent
dual V1a/V2 receptor antagonists and exhibit an unforeseeable,
valuable spectrum of pharmacological action. They are therefore
suitable for use as medicaments for treatment and/or prophylaxis of
diseases in humans and animals.
[0151] The compounds according to the invention, on their own or in
combination with one or more other active ingredients, are suitable
for prevention and/or treatment of various disorders, for example
disorders of the cardiovascular system (cardiovascular disorders),
for cardioprotection after damage to the heart and of metabolic and
kidney disorders.
[0152] The compounds according to the invention, on their own or in
combination with one or more other active ingredients, are suitable
for prevention and/or treatment of various disorders, for example
disorders of the cardiovascular system (cardiovascular disorders),
and of renal disorders.
[0153] The compounds according to the invention have valuable
pharmacological properties and can be used for prevention and/or
treatment of various disorders and disease-related conditions in
humans and animals.
[0154] Possible target indications are listed by way of example and
with preference in WO 2016/071212, pages 16 to 19.
[0155] Suitable combination active ingredients and dosage forms are
listed by way of example and with preference in WO 2016/071212,
pages 19 to 27.
[0156] The working examples which follow illustrate the invention.
The invention is not restricted to the examples.
[0157] Unless stated otherwise, the percentages in the tests and
examples which follow are percentages by weight; parts are parts by
weight. Solvent ratios, dilution ratios and concentration data for
liquid/liquid solutions are based in each case on volume.
A. EXAMPLES
Abbreviations
[0158] aq. aqueous, aqueous solution c concentration cat. catalytic
CDI N,N'-carbonyldiimidazole DCI direct chemical ionization (in MS)
dist. distilled
DIEA N,N-diisopropylethylamine
DMAP 4-N,N-dimethylaminopyridine
[0159] DMF dimethylformamide DMSO dimethyl sulphoxide ee
enantiomeric excess ent enantiomerically pure, enantiomer eq.
equivalent(s) ESI electrospray ionization (in MS) Et ethyl GC-MS
gas chromatography-coupled mass spectrometry h hour(s) HPLC
high-pressure, high-performance liquid chromatography conc.
concentrated LC-MS liquid chromatography-coupled mass spectrometry
Me methyl min minute(s) MS mass spectrometry MtBE methyl tert-butyl
ether NMR nuclear magnetic resonance spectrometry Ph phenyl quant.
quantitative (in yield) rac racemic, racemate RT room temperature
R.sub.t retention time (in HPLC) THF tetrahydrofuran UV ultraviolet
spectrometry v/v volume to volume ratio (of a solution)
[0160] LC/MS and HPLC methods:
[0161] Method 1 (LC/MS): MCW-SO-HSST3
[0162] Instrument: Waters Acquity SQD UPLC System; column: Waters
Acquity UPLC HSS T3 1.8 .mu., 50 mm.times.1 mm; eluent A: 1 l
water+0.25 ml 99% formic acid, eluent B: 1 l acetonitrile+0.25 ml
99% formic acid; gradient: 0.0 min 90% A.fwdarw.1.2 min 5%
A.fwdarw.2.0 min 5% A; oven: 50.degree. C.; flow rate: 0.40 ml/min;
UV detection: 208-400 nm.
[0163] Method 2 (LC/MS): MCW-FT-MS-M1
[0164] Instrument: Thermo Scientific FT-MS; instrument UHPLC+:
Thermo Scientific UltiMate 3000; column: Waters, HSST3,
2.1.times.75 mm, C18 1.8 .mu.m; Eluent A: 1 l water+0.01% formic
acid; eluent B: 1 l acetonitrile+0.01% formic acid; gradient: 0.0
min 10% B.fwdarw.2.5 min 95% B.fwdarw.3.5 min 95% B; oven:
50.degree. C.; flow: 0.90 ml/min; UV detection: 210 nm/Optimum
Integration Path 210-300 nm
[0165] Further Details:
[0166] The percentages in the example and test descriptions which
follow are, unless indicated otherwise, percentages by weight;
parts are parts by weight. Solvent ratios, dilution ratios and
concentration data for liquid/liquid solutions are based in each
case on volume.
[0167] In the case of purifications of compounds of the invention
by preparative HPLC by the above-described methods in which the
eluents contain additives, for example trifluoroacetic acid, formic
acid or ammonia, the compounds of the invention can be obtained in
salt form, for example as trifluoroacetate, formate or ammonium
salt, if the compounds of the invention contain a sufficiently
basic or acidic functionality. Such a salt can be converted to the
corresponding free base or acid by various methods known to the
person skilled in the art.
[0168] Purity figures are generally based on corresponding peak
integrations in the LC/MS chromatogram, but may additionally also
have been determined with the aid of the .sup.1H NMR spectrum. If
no purity is indicated, the purity is generally 100% according to
automated peak integration in the LC/MS chromatogram, or the purity
has not been determined explicitly.
[0169] Stated yields in % of theory are generally corrected for
purity if a purity of <100% is indicated. In solvent-containing
or contaminated batches, the formal yield may be ">100%"; in
these cases the yield is not corrected for solvent or purity.
[0170] The descriptions of the coupling patterns of .sup.1H NMR
signals that follow have in some cases been taken directly from the
suggestions of the ACD SpecManager (ACD/Labs Release 12.00, Product
version 12.5) and have not necessarily been strictly scrutinized.
In some cases, the suggestions of the SpecManager were adjusted
manually. Manually adjusted or assigned descriptions are generally
based on the optical appearance of the signals in question and do
not necessarily correspond to a strict, physically correct
interpretation. In general, the stated chemical shift refers to the
centre of the signal in question. In the case of broad multiplets,
an interval is given. Signals obscured by solvent or water were
either tentatively assigned or have not been listed. Significantly
broadened signals--caused, for example, by rapid rotation of
molecular moieties or because of exchanging protons--were likewise
assigned tentatively (often referred to as a broad multiplet or
broad singlet) or are not listed.
[0171] The .sup.1H NMR data of selected examples are stated in the
form of .sup.1H NMR peak lists. For each signal peak, first the
.delta. value in ppm and then the signal intensity in round
brackets are listed. The .delta. value/signal intensity number
pairs for different signal peaks are listed with separation from
one another by commas. The peak list for an example therefore takes
the following form: .delta..sub.1 (intensity.sub.1), .delta..sub.2
(intensity.sub.2), . . . , .delta..sub.i (intensity.sub.i), . . . ,
.delta..sub.n (intensity.sub.n).
[0172] The intensity of sharp signals correlates with the height of
the signals in a printed example of an NMR spectrum in cm and shows
the true ratios of the signal intensities in comparison with other
signals. In the case of broad signals, several peaks or the middle
of the signal and the relative intensity thereof may be shown in
comparison to the most intense signal in the spectrum. The lists of
the .sup.1H NMR peaks are similar to the conventional .sup.1H NMR
printouts and thus usually contain all peaks listed in a
conventional NMR interpretation. In addition, like conventional
.sup.1H NMR printouts, they may show solvent signals, signals of
stereoisomers of the target compounds which are likewise provided
by the invention, and/or peaks of impurities. The peaks of
stereoisomers of the target compounds and/or peaks of impurities
usually have a lower intensity on average than the peaks of the
target compounds (for example with a purity of >90%). Such
stereoisomers and/or impurities may be typical of the particular
preparation process. Their peaks can thus help in identifying
reproduction of our preparation process with reference to
"by-product fingerprints". An expert calculating the peaks of the
target compounds by known methods (MestreC, ACD simulation, or
using empirically evaluated expected values) can, if required,
isolate the peaks of the target compounds, optionally using
additional intensity filters. This isolation would be similar to
the peak picking in question in conventional .sup.1H NMR
interpretation. A detailed description of the presentation of NMR
data in the form of peak lists can be found in the publication
"Citation of NMR Peaklist Data within Patent Applications" (cf.
Research Disclosure Database Number 605005, 2014, 1 Aug. 2014 or
http: // world wide web. researchdisclosure.com/
searching-disclosures). In the peak picking routine described in
Research Disclosure Database Number 605005, the parameter
"MinimumHeight" can be set between 1% and 4%. Depending on the type
of chemical structure and/or depending on the concentration of the
compound to be analysed, it may be advisable to set the parameters
"MinimumHeight" to values of <1%.
[0173] Melting points and melting point ranges, if stated, are
uncorrected.
[0174] All reactants or reagents whose preparation is not described
explicitly hereinafter were purchased commercially from generally
accessible sources. For all other reactants or reagents whose
preparation likewise is not described hereinafter and which were
not commercially obtainable or were obtained from sources which are
not generally accessible, a reference is given to the published
literature in which their preparation is described.
WORKING EXAMPLES
Example 1
{3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dih-
ydro-1H-1,2,4-triazol-1-yl}acetonitrile (X-a)
##STR00039##
[0176] 100 g (0.325 mol) of
5-(4-chlorophenyl)-4-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-2,4-dihydro-3-
H-1,2,4-triazol-3-one (II-A) (synthesis described as Example 5A in
WO 2010/105770 A1) as a solution in 1.0 l of methyl isobutyl ketone
were initially charged together with 135 g (0.975 mol) of sodium
carbonate and then the mixture was heated to 60.degree. C.
Subsequently, at this temperature, 27 g (0.358 mol) of
chloroacetonitrile dissolved in 270 ml of methyl isobutyl ketone
(IX) were homogeneously added dropwise over a period of 6 h. The
mixture was stirred at 60.degree. C. for a further 15 h and then
cooled to 20.degree. C., 500 ml of water were added, the mixture
was stirred and the organic phase was removed. The organic phase
was washed once again with 500 ml of water, and then concentrated
to a volume of about 250 ml under reduced pressure at a jacket
temperature of 60.degree. C. Subsequently, 250 ml of n-heptane were
added, and the product crystallized out. To complete the
crystallization, with simultaneous addition of 500 ml of n-heptane
at a jacket temperature of 60.degree. C., about 500 ml of the
solvent mixture were distilled off under reduced pressure. The
mixture was cooled to 20.degree. C. and stirred at this temperature
for one hour. The product was filtered off and washed with
n-heptane (2.times.150 ml). The product was dried at 40.degree. C.
under reduced pressure. Yield: 81 g (72% of theory) of a solid.
[0177] MS (EIpos): m/z=347.1 [M+H]+
[0178] 1H-NMR (400 MHz, DMSO-d6): .delta.=3.81 (dd, 1H), 3.98 (dd,
1H), 4.23-4.34 (m, 1H), 5.17 (s, 2H), 6.91 (d, 1H), 7.55 (d, 2H),
7.78 (d, 2H).
Example 2
Methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl-
]-4,5-dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI-a)
##STR00040##
[0180] 200 g (576.9 mmol) of
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetonitrile (X-a) were initially
charged as a solution in 1.6 l of methanol, and 5.2 g (28 mmol) of
sodium methoxide (30% in methanol) were added. The mixture was
stirred at 50.degree. C. for 2 hours and then concentrated at a
jacket temperature of 50.degree. C. to give the oily residue. 2 l
of MtBE were added and the mixture was concentrated to a volume of
about 0.8 l. The solution was then gradually metered into 4 l of
n-hexane while stirring. In the course of this, the product
crystallized out as a thick crystal suspension. The mixture was
left to cool to 20.degree. C. and stirred at room temperature for
one hour. The product was filtered off and washed with n-hexane
(2.times.0.25 l). The product was dried at 40.degree. C. under
reduced pressure.
[0181] Yield: 175 g (80% of theory) of a solid.
[0182] 1H-NMR (400 MHz, DMSO-d6): .delta.=3.67 (s, 3H), 3.81 (dd,
1H), 3.96 (dd, 1H), 4.23-4.35 (m, 1H), 4.50 (s, 2H), 6.93 (br. s,
1H), 7.62 (d, 2H), 7.78 (d, 2H), 8.01 (s, 1H).
Example 3
(5-(4-Chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,-
4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydr-
o-3H-1,2,4-triazol-3-one (I-A-1)
##STR00041##
[0184] Process Variant B:
[0185] Methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI-a) (164 g, 433 mmol)
was dissolved in a mixture of THF (1.01) and toluene (0.5 l). The
mixture was admixed with N-ethyldiisopropylamine (97.8 g, 757 mmol)
and then stirred at 20.degree. C. for 15 min. Subsequently, at
0.degree. C., (S)-2-acetoxypropionyl chloride (XII-A) (78.2 g, 519
mmol) was metered in and the mixture was stirred at 0.degree. C.
for 1 h. Subsequently, at 0.degree. C., a solution of
4-chlorophenylhydrazine hydrochloride (XIII-1) (85.2 g, 476 mmol)
and N-ethyldiisopropylamine (67.11 g, 519 mmol) in THF (0.5 l) was
metered in, with removal of precipitated N-ethyldiisopropylamine
hydrochloride prior to the metered addition, then the mixture was
stirred at 20.degree. C. for 1 h and at reflux temperature (about
75.degree. C.) for a further 2 h. The mixture was left to cool to
20.degree. C. and 0.75 l of water was added to the mixture. After
phase separation, the organic phase was washed twice with 0.5 l
each time of a 1 N hydrochloric acid solution, and then the mixture
was concentrated under reduced pressure to the oily residue at a
jacket temperature of 80.degree. C. and co-distilled twice with 1.0
l each time of methanol. The oily residue was then dissolved in 0.6
l of methanol, 0.5 l of a 1 N sodium hydroxide solution was added
at 0.degree. C., and the mixture was stirred at 20.degree. C. for 1
h. After addition of 0.75 l of water and 0.75 l of MtBE, the
organic phase was removed, washed twice with 0.3 l each time of
semi-saturated aqueous sodium chloride solution, and then
concentrated at a jacket temperature of 80.degree. C. under reduced
pressure down to a volume of about 0.3 l. After addition of 1.5 l
of diisopropyl ether, the mixture was again concentrated at a
jacket temperature of 80.degree. C. under reduced pressure down to
a volume of about 0.3 l, and the product precipitates out. The
mixture was cooled to 10.degree. C. and stirred at this temperature
for one hour. The product was filtered off and washed with 0.3 l of
diisopropyl ether. The product was dried at 50.degree. C. under
reduced pressure. Yield: 200 g (72% of theory).
[0186] MS (ESIpos): m/z (%)=543.1 (100) [M+H].sup.+.
[0187] 1H-NMR (400 MHz, DMSO-d6): .delta.=1.47 (d, 3H), 3.85 (dd,
1H), 4.00 (dd, 1H), 4.24-4.36 (m, 1H), 4.81 (quin, 1H), 5.07 (s,
2H), 5.75 (d, 1H), 6.89 (d, 1H), 7.54-7.66 (m, 5H), 7.72-7.79 (m,
3H).
[0188] Process Variant C (with Subsequent Crystallization from
Methyl Tert-Butyl Ether/Diisopropyl Ether):
[0189] 1.373 kg (3.96 mol) of
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetonitrile (X-a) were initially
charged as a solution in 6.9 l of methanol, and 36 g (0.198 mol) of
sodium methoxide (30% in methanol) were added. The mixture was
stirred at 50.degree. C. for 1.5 hours and then concentrated at a
jacket temperature of 50.degree. C. to give the still-stirrable,
slurry-like residue. Three times, 3.0 l of toluene were added and
the mixture was concentrated to a volume of 5 l in each case. THF
(9.5 l) and toluene (2.5 l) were added to the residue,
N-ethyldiisopropylamine (0.896 kg, 6.93 mol) was added at
20.degree. C., and the mixture was stirred at 20.degree. C. for a
further 15 min. Subsequently, at 0.degree. C.,
(S)-2-acetoxypropionyl chloride (XII-A) (0.715 kg, 4.752 mol) was
metered in and the mixture was stirred at 0.degree. C. for 1 h.
Subsequently, at 0.degree. C., a solution of
4-chlorophenylhydrazine hydrochloride (XIII-1) (0.78 kg, 4.356 mol)
and N-ethyldiisopropylamine (0.614 kg, 4.752 mol) in THF (4.5 l)
was metered in, with removal of precipitated
N-ethyldiisopropylamine hydrochloride prior to the metered
addition, then the mixture was stirred at 20.degree. C. for 1 h and
at reflux temperature (about 75.degree. C.) for a further 2 h. The
mixture was left to cool to 20.degree. C. and 7.0 l of water were
added to the mixture. After phase separation, the organic phase was
washed twice with 3.5 l each time of a 1 N hydrochloric acid
solution, and the mixture was concentrated under reduced pressure
to the oily residue at a jacket temperature of 80.degree. C. and
co-distilled twice with 13.5 l each time of methanol. The oily
residue was dissolved in 5.5 l of methanol, 4.0 l of a 1 N sodium
hydroxide solution was added at 0.degree. C., and the mixture was
stirred at 20.degree. C. for 1 h. After addition of 7.0 l of water
and 7.0 l of MtBE, the organic phase was removed, washed twice with
2.75 l each time of semi-saturated aqueous sodium chloride
solution, and concentrated at a jacket temperature of 80.degree. C.
under reduced pressure down to a volume of about 3.0 l. After
addition of 16.0 l of diisopropyl ether, the mixture was again
concentrated at a jacket temperature of 80.degree. C. under reduced
pressure down to a volume of about 6.0 l, and the product
precipitated out. The mixture then was cooled to 10.degree. C. and
stirred at this temperature for one hour. The product was filtered
off and washed twice with 1.0 l each time of diisopropyl ether. The
product was dried at 50.degree. C. under reduced pressure. Yield:
1.680 kg (78% of theory).
[0190] Purity of >99%; optical purity >>99% e.e.
[0191] Process Variant C (with Subsequent Crystallization from
Methyl Tert-Butyl Ether/n-Heptane):
[0192] 50 g (144 mmol) of
{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}acetonitrile (X-a) were initially
charged as a solution in 250 ml of methanol, and 1.58 g (7.3 mmol)
of sodium methoxide (25% in methanol) were added. The mixture was
stirred at 50.degree. C. for 1.5 hours and then concentrated at a
jacket temperature of 50.degree. C. to give the still-stirrable,
slurry-like residue. Three times, the mixture was admixed with 200
ml each time of DMF and concentrated to dryness under reduced
pressure. 325 ml of THF were added to the residue,
N-ethyldiisopropylamine (44 ml, 253 mmol) was added at 20.degree.
C., and the mixture was stirred at 20.degree. C. for a further 15
min. Subsequently, at 0.degree. C., (S)-2-acetoxypropionyl chloride
(XII-A) (26 g, 173 mmol) was metered in and the mixture was stirred
at 0.degree. C. for 1 h. Subsequently, at 0.degree. C., a solution
of 4-chlorophenylhydrazine hydrochloride (XIII-1) (28.5 g, 159
mmol) and N-ethyldiisopropylamine (30 ml, 172 mmol) in 150 ml of
THF was metered in, with removal of precipitated
N-ethyldiisopropylamine hydrochloride prior to the metered
addition. Subsequently, the mixture was stirred at 20.degree. C.
for 30 min and at reflux temperature (about 75.degree. C.) for a
further 2.5 h. The mixture was left to cool to 20.degree. C. and
125 ml of MtBE and 250 ml of water were added to the mixture. After
phase separation, the organic phase was washed twice with 125 g
each time of a 1 N hydrochloric acid solution, and the mixture was
concentrated under reduced pressure to the oily residue at a jacket
temperature of 60.degree. C. and co-distilled twice with 500 ml
each time of methanol. The oily residue was dissolved in 200 ml of
methanol, 35 ml of a 1 N sodium hydroxide solution were added at
0.degree. C., and the mixture was stirred at 20.degree. C. for 1 h.
After addition of 175 ml of water and 375 ml of MtBE, the organic
phase was removed, washed twice with 62 ml each time of
semi-saturated aqueous sodium chloride solution, and concentrated
at a jacket temperature of 80.degree. C. under reduced pressure to
an oily residue. After addition of 300 ml of diisopropyl ether, the
mixture was again concentrated at a jacket temperature of
80.degree. C. under reduced pressure down to a volume of about 150
ml, and the product precipitates out. The mixture then was cooled
to 10.degree. C. and stirred at this temperature for one hour. The
product was filtered off and washed twice with 100 ml each time of
diisopropyl ether. The product was dried at 50.degree. C. under
reduced pressure. The crystals were dissolved in 420 ml of MtBE
under reflux. After addition of 900 ml of n-heptane at 50.degree.
C., the product crystallizes out. The mixture then was cooled to
20.degree. C. and stirred at this temperature for one hour. The
product was filtered off, washed with 100 ml of n-heptane and dried
at 70.degree. C. under reduced pressure. Yield: 58 g (74% of
theory).
[0193] Purity of >99%; optical purity >>99% e.e.
Example 4
a)
(1R)-1-[1-(3-Chlorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-t-
rifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-1,2-
,4-triazol-5-yl]ethyl Acetate (XIV-B-1)
[0194] While cooling with ice, 87 mg (0.58 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 200 mg (0.53 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 262 .mu.l (1.5
mmol) of DIPEA in 2 ml of THF. After 1 h at 0.degree. C., 104 mg
(0.58 mmol) of 3-chlorophenylhydrazine (XIII) were added and then
the mixture was stirred at RT overnight. The reaction mixture was
purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 208 mg (64% of theory) of the
title compound.
[0195] LC-MS (Method 2): R.sub.t=2.04 min; MS(ESIpos): m/z=585.1
[M+H].sup.+
[0196] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.90-7.37 (m,
8H), 6.89 (d, 1H), 5.91 (d, 1H), 5.09 (s, 2H), 4.40-4.20 (m, 1H),
4.09-3.71 (m, 2H), 1.81 (s, 3H), 1.56 (d, 3H)
b)
2-({1-(3-Chlorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}me-
thyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihy-
dro-3H-1,2,4-triazol-3-one (I-B-1)
##STR00042##
[0198] A mixture of 200 mg (0.34 mmol) of the compound from step a)
and 341 .mu.l (0.34 mmol) of 1 M sodium hydroxide solution in 2.6
ml of methanol was stirred at RT for 30 min. 1 g of activated ion
exchanger (Dowex 50WX8, 200-400 mesh) was added and the mixture was
stirred at RT for 5 min. The ion exchanger was then filtered off,
and washed with methanol.
[0199] The filtrate was concentrated. This gave 168 mg (90% of
theory) of the title compound.
[0200] LC-MS (Method 2): R.sub.t=1.85 min; MS(ESIpos): m/z=543.1
[M+H].sup.+
[0201] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.98-7.48 (m,
8H), 6.90 (d, 1H), 5.76 (d, 1H), 5.07 (s, 2H), 4.81 (t, 1H),
4.46-3.68 (m, 3H), 1.47 (d, 3H).
Example 5
a)
(1S)-1-[3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(2,4-dichlorophenyl)-1H-
-1,2,4-triazol-5-yl]ethyl Acetate (XIV-A-2)
[0202] While cooling with ice, 73 .mu.l (0.58 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 200 mg (0.53 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 262 .mu.l (1.51
mmol) of DIPEA in 2 ml of THF. After 1 h at 0.degree. C., 124 mg
(0.58 mmol) of 2,4-dichlorophenylhydrazine hydrochloride (XIII)
were added and then the mixture was stirred at RT overnight. The
reaction mixture was heated under reflux for 2 h and heated in the
microwave at 100.degree. C. for 5 h. The solvent was removed under
reduced pressure and the crude product was purified by
chromatography (preparative HPLC, eluent: acetonitrile/water
gradient, 0.1% formic acid). Lyophilization of the
product-containing fractions gave 163 mg (48% of theory) of the
title compound.
[0203] LC-MS (Method A): R.sub.t=1.13 min; MS(ESIpos): m/z=619.0
[M+H].sup.+
[0204] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.04-7.49 (m,
7H), 6.89 (d, 1H), 5.90-5.44 (m, 1H), 5.10 (d, 2H), 4.45-4.16 (m,
1H), 4.11-3.73 (m, 2H), 1.81 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-(2,4-dichlorophenyl)-5-[(1S)-1-hydroxyethyl]-1-
H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4--
dihydro-3H-1,2,4-triazol-3-one (I-A-2)
##STR00043##
[0206] A mixture of 160 mg (0.26 mmol) of the compound from step a)
and 258 .mu.l (0.26 mmol) of 1 M sodium hydroxide solution in 2 ml
of methanol was stirred at 0.degree. C. for 2 min and at RT for 90
min. 1 g of activated ion exchanger (Dowex 50WX8, 200-400 mesh) was
added and the mixture was stirred at RT for 30 min. The ion
exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 148 mg (quant.) of the title compound.
[0207] LC-MS (Method A): R.sub.t=1.02 min; MS(ESIpos): m/z=577.1
[M+H].sup.+
[0208] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.92 (d, 1H),
7.78-7.71 (m, 2H), 7.68-7.58 (m, 4H), 6.89 (d, 1H), 5.52 (d, 1H),
5.06 (d, 2H), 4.64 (s, 1H), 4.43-4.21 (m, 1H), 4.08-3.72 (m, 2H),
1.39 (d, 3H)
Example 6
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(difluoromethoxy)phe-
nyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-3)
[0209] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 76
mg (0.44 mmol) of 2-difluoromethoxyphenylhydrazine (XIII) were
added and then the mixture was stirred at RT overnight. The
reaction mixture was then heated in the microwave at 100.degree. C.
for 3 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 142 mg (58% of theory) of the
title compound.
[0210] LC-MS (Method A): R.sub.t=1.09 min; MS(ESIpos): m/z=617.1
[M+H].sup.+
[0211] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.83-6.82 (m,
10H), 5.69 (d, 1H), 5.09 (d, 2H), 4.30 (d, 1H), 4.07-3.77 (m, 2H),
1.77 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[2-(difluoromethoxy)phenyl]-5-[(1S)-1-hydroxye-
thyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropy-
l]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-3)
##STR00044##
[0213] A mixture of 132 mg (0.21 mmol) of the compound from step a)
and 214 .mu.l (0.21 mmol) of 1 M sodium hydroxide solution in 1.3
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 117 mg (95% of theory) of the title
compound.
[0214] LC-MS (Method A): R.sub.t=0.99 min; MS(ESIpos): m/z=575.3
[M+H].sup.+
[0215] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.75 (d, 2H),
7.67-7.54 (m, 4H), 7.45-6.97 (m, 3H), 6.89 (d, 1H), 5.48 (d, 1H),
5.19-4.94 (m, 2H), 4.61 (quin, 1H), 4.30 (d, 1H), 4.09-3.76 (m,
2H), 1.39 (d, 3H)
Example 7
a)
(1R)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(difluoromethoxy)phe-
nyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-B-3)
[0216] While cooling with ice, 73 .mu.l (0.58 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 200 mg (0.53 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 276 .mu.l (1.58
mmol) of DIPEA in 2 ml of THF. After 30 min at 0.degree. C., 101 mg
(0.58 mmol) of 2-difluoromethoxyphenylhydrazine (XIII) were added
and then the mixture was stirred at RT overnight. The reaction
mixture was then heated in the microwave at 150.degree. C. for 3 h.
A few drops of water were added to the reaction mixture, which was
purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 202 mg (62% of theory) of the
title compound.
[0217] LC-MS (Method A): R.sub.t=1.09 min; MS(ESIpos): m/z=617.3
[M+H].sup.+
[0218] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.89-6.81 (m,
10H), 5.79-5.59 (m, 1H), 5.09 (d, 2H), 4.35-4.22 (m, 1H), 4.09-3.78
(m, 2H), 1.76 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[2-(difluoromethoxy)phenyl]-5-[(1R)-1-hydroxye-
thyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropy-
l]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-B-3)
##STR00045##
[0220] A mixture of 192 mg (0.31 mmol) of the compound from step a)
and 310 .mu.l (0.31 mmol) of 1 M sodium hydroxide solution in 1.9
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 172 mg (96% of theory) of the title
compound.
[0221] LC-MS (Method A): R.sub.t=0.99 min; MS(ESIpos): m/z=575.3
[M+H].sup.+
[0222] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.75 (d, 2H),
7.68-7.53 (m, 4H), 7.46-6.96 (m, 3H), 6.91 (d, 1H), 5.48 (d, 1H),
5.06 (s, 2H), 4.61 (t, 1H), 4.30 (d, 1H), 4.07-3.75 (m, 1H), 1.39
(d, 1H)
Example 8
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}ylmethyl)[2-chloro-4-(trifluorome-
thyl)phenyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-4)
[0223] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 91
mg (0.44 mmol) of 2-chloro-4-(trifluoromethyl)phenylhydrazine
(XIII) were added and the mixture was stirred at RT for 1 h. The
reaction mixture was then heated in the microwave at 100.degree. C.
for 3 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 111 mg (43% of theory) of the
title compound.
[0224] LC-MS (Method A): R.sub.t=1.21 min; MS(ESIpos): m/z=653.1
[M+H].sup.+
[0225] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.25 (s, 1H),
8.06-7.87 (m, 2H), 7.81-7.54 (m, 4H), 6.89 (d, 1H), 5.75 (s, 1H),
5.12 (d, 2H), 4.29 (d, 1H), 4.07-3.77 (m, 2H), 1.76 (s, 3H), 1.55
(d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[2-chloro-4-(trifluoromethyl)phenyl]-5-[(1S)-1-
-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hyd-
roxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-4)
##STR00046##
[0227] A mixture of 104 mg (0.16 mmol) of the compound from step a)
and 160 .mu.l (0.16 mmol) of 1 M sodium hydroxide solution in 1 ml
of methanol was stirred at 0.degree. C. for 2 min and at RT for 90
min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400 mesh)
was added and the mixture was stirred at RT for 30 min. The ion
exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 94 mg (96% of theory) of the title
compound.
[0228] LC-MS (Method A): R.sub.t=1.06 min; MS(ESIpos): m/z=611.1
[M+H].sup.+
[0229] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.18 (s, 1H),
7.99-7.82 (m, 2H), 7.75 (d, 2H), 7.62 (d, 2H), 6.89 (d, 1H), 5.54
(d, 1H), 5.08 (d, 2H), 4.71 (t, 1H), 4.29 (d, 1H), 4.11-3.77 (m,
2H), 1.41 (d, 3H)
Example 9
a)
(1S)-1-[1-(2-Chloro-6-fluorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S-
)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methy-
l)-1H-1,2,4-triazol-5-yl]ethyl acetate (XIV-A-5)
[0230] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 70
mg (0.44 mmol) of (2-chloro-6-fluorophenyl)phenylhydrazine (XIII)
were added and the mixture was stirred at RT for 1 h. The reaction
mixture was then heated in the microwave at 100.degree. C. for 3 h.
A few drops of water were added to the reaction mixture, which was
purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 139 mg (58% of theory) of the
title compound as an atropisomer mixture.
[0231] LC-MS (Method A): R.sub.t=1.10 min; MS(ESIpos): m/z=603.1
[M+H].sup.+
[0232] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.82-7.50 (m,
7H), 6.89 (d, 1H), 5.73 (d, 1H), 5.25-5.04 (m, 2H), 4.43-4.19 (m,
1H), 4.10-3.78 (m, 2H), 1.79 (s, 3H), 1.54 (m, 3H)
b)
2-({1-(2-Chloro-6-fluorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazo-
l-3-yl}methyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-
-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-5)
##STR00047##
[0234] A mixture of 129 mg (0.21 mmol) of the compound from step a)
and 214 .mu.l (0.21 mmol) of 1 M sodium hydroxide solution in 1.3
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 114 mg (95% of theory) of the title compound as
an atropisomer mixture.
[0235] LC-MS (Method A): R.sub.t=0.99 min; MS(ESIpos): m/z=561.3
[M+H].sup.+
[0236] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.79-7.46 (m,
7H), 6.89 (d, 1H), 5.60 (dd, 1H), 5.22-4.97 (m, 2H), 4.84-4.55 (m,
1H), 4.29 (d, 1H), 4.08-3.73 (m, 2H), 1.44-1.33 (m, 3H)
Example 10
a)
(1R)-1-[1-(2-Chloro-6-fluorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S-
)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methy-
l)-1H-1,2,4-triazol-5-yl]ethyl acetate (XIV-B-5)
[0237] While cooling with ice, 55 .mu.l (0.44 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 70
mg (0.44 mmol) of 2-chloro-6-fluorophenylhydrazine (XIII) were
added and then the mixture was stirred at RT overnight. The
reaction mixture was then heated in the microwave at 150.degree. C.
for 1 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 162 mg (68% of theory) of the
title compound as a mixture of atropisomers.
[0238] LC-MS (Method A): R.sub.t=1.10 min; MS(ESIpos): m/z=603.3
[M+H]
[0239] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.83-7.49 (m,
7H), 6.96-6.84 (m, 1H), 5.73 (d, 1H), 5.13 (d, 2H), 4.29 (br. s.,
1H), 4.09-3.76 (m, 2H), 1.79 (d, 3H), 1.54 (dd, 3H)
b)
2-({1-(2-Chloro-6-fluorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazo-
l-3-yl}methyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-
-2,4-dihydro-3H-1,2,4-triazol-3-one (I-B-5)
##STR00048##
[0241] A mixture of 152 mg (0.25 mmol) of the compound from step a)
and 250 .mu.l (0.25 mmol) of 1 M sodium hydroxide solution in 1.5
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 137 mg (95% of theory) of the title compound as
an atropisomer mixture.
[0242] LC-MS (Method A): R.sub.t=0.99 min; MS(ESIpos): m/z=561.2
[M+H].sup.+
[0243] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.83-7.43 (m,
7H), 6.90 (d, 1H), 5.60 (dd, 1H), 5.26-4.92 (m, 2H), 4.84-4.54 (m,
1H), 4.29 (d, 1H), 4.11-3.72 (m, 2H), 1.44-1.33 (m, 3H)
Example 11
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[4-fluoro-2-(trifluorom-
ethyl)phenyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-6)
[0244] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 100
mg (0.44 mmol) of 4-fluoro-2-(trifluoromethyl)phenylhydrazine
(XIII) hydrochloride were added and the mixture was stirred at RT
for 3 h. The reaction mixture was then heated in the microwave at
150.degree. C. for 3 h. A few drops of water were added to the
reaction mixture, which was purified by chromatography (preparative
HPLC, eluent: acetonitrile/water gradient, 0.1% formic acid).
Lyophilization of the product-containing fractions gave 129 mg (51%
of theory) of the title compound.
[0245] LC-MS (Method A): R.sub.t=1.14 min; MS(ESIpos): m/z=637.3
[M+H].sup.+
[0246] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.05-7.54 (m,
7H), 6.88 (d, 1H), 5.75 (s, 1H), 5.09 (d, 2H), 4.38-4.18 (m, 1H),
4.08-3.74 (m, 2H), 1.78 (br. s., 3H), 1.51 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(1S)-1-
-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hyd-
roxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-6)
##STR00049##
[0248] A mixture of 119 mg (0.19 mmol) of the compound from step a)
and 187 .mu.l (0.19 mmol) of 1 M sodium hydroxide solution in 1.1
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 110 mg (quant.) of the title compound.
[0249] LC-MS (Method A): R.sub.t=1.03 min; MS(ESIpos): m/z=595.1
[M+H].sup.+
[0250] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.96-7.87 (m,
1H), 7.83-7.55 (m, 6H), 6.89 (d, 1H), 5.50 (d, 1H), 5.16-4.94 (m,
2H), 4.69-4.50 (m, 1H), 4.28 (br. s., 1H), 4.07-3.75 (m, 2H), 1.37
(d, 3H)
Example 12
a)
(1S)-1-[1-(2-Chloro-4-fluorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S-
)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methy-
l)-1H-1,2,4-triazol-5-yl]ethyl acetate (XIV-A-7)
[0251] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 85
mg (0.44 mmol) of 2-chloro-4-fluorophenylhydrazine hydrochloride
(XIII) were added and the mixture was stirred at RT for 2 h. The
reaction mixture was then heated in the microwave at 150.degree. C.
for 3 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 157 mg (66% of theory) of the
title compound.
[0252] LC-MS (Method A): R.sub.t=1.07 min; MS(ESIpos): m/z=603.0
[M+H].sup.+
[0253] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.90-7.33 (m,
7H), 6.88 (d, 1H), 5.96-5.47 (m, 1H), 5.10 (d, 2H), 4.29 (d, 1H),
4.11-3.74 (m, 2H), 1.82 (br. s., 3H), 1.53 (d, 3H)
b)
2-({1-(2-Chloro-4-fluorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazo-
l-3-yl}methyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-
-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-7)
##STR00050##
[0255] A mixture of 152 mg (0.25 mmol) of the compound from step A)
and 252 .mu.l (0.25 mmol) of 1 M sodium hydroxide solution in 1.5
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 140 mg (quant.) of the title compound.
[0256] LC-MS (Method A): R.sub.t=1.00 min; MS(ESIpos): m/z=561.2
[M+H].sup.+
[0257] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.84-7.54 (m,
6H), 7.42 (td, 1H), 6.89 (d, 1H), 5.51 (d, 1H), 5.06 (d, 2H),
4.72-4.51 (m, 1H), 4.40-4.19 (m, 1H), 4.10-3.74 (m, 2H), 1.38 (d,
3H)
Example 13
a)
(1R)-1-[1-(2-Chloro-4-fluorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S-
)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methy-
l)-1H-1,2,4-triazol-5-yl]ethyl acetate (XIV-B-7)
[0258] While cooling with ice, 109 mg (0.73 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 250 mg (0.66 mmol) of methyl
5-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 345 .mu.l (1.98
mmol) of DIPEA in 2 ml of THF. After 30 min at 0.degree. C., 143 mg
(0.73 mmol) of 2-chloro-4-fluorophenylhydrazine hydrochloride
(XIII) were added and then the mixture was stirred at RT overnight.
The reaction mixture was subsequently heated in the microwave at
120.degree. C. for 3 h and purified by chromatography (preparative
HPLC, eluent: acetonitrile/water gradient, 0.1% formic acid).
Lyophilization of the product-containing fractions gave 177 mg (44%
of theory) of the title compound.
[0259] LC-MS (Method A): R.sub.t=1.10 min; MS(ESIpos): m/z=603.2
[M+H].sup.+
[0260] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.96-7.31 (m,
7H), 6.89 (d, 1H), 5.75 (s, 1H), 5.26-4.96 (m, 2H), 4.29 (br. s.,
1H), 4.10-3.76 (m, 2H), 1.82 (br. s., 3H), 1.53 (d, 3H)
b)
2-({1-(2-Chloro-4-fluorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazo-
l-3-yl}methyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-
-2,4-dihydro-3H-1,2,4-triazol-3-one (I-B-7)
##STR00051##
[0262] A mixture of 165 mg (0.27 mmol) of the compound from step a)
and 275 .mu.l (0.27 mmol) of 1 M sodium hydroxide solution in 3.3
ml of methanol was stirred at RT for 30 min. A few drops of 50%
aqueous formic acid were added to the reaction mixture, which was
purified by means of preparative HPLC (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 144 mg (93% of theory) of the
title compound.
[0263] LC-MS (Method A): R.sub.t=0.96 min; MS(ESIpos): m/z=561.00
[M+H].sup.+
[0264] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.89-7.54 (m,
6H), 7.42 (td, 1H), 6.90 (d, 1H), 5.51 (d, 1H), 5.06 (s, 2H),
4.72-4.51 (m, 1H), 4.30 (d, 1H), 4.12-3.75 (m, 2H), 1.38 (d,
3H)
Example 14
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[4-chloro-2-(trifluorom-
ethyl)phenyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-8)
[0265] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 107
mg (0.44 mmol) of 4-chloro-2-(trifluoromethyl)phenylhydrazine
hydrochloride (XIII) were added and the mixture was stirred at RT
for 3 h. The reaction mixture was then heated in the microwave at
150.degree. C. for 3 h. A few drops of water were added to the
reaction mixture, which was purified by chromatography (preparative
HPLC, eluent: acetonitrile/water gradient, 0.1% formic acid).
Lyophilization of the product-containing fractions gave 125 mg (48%
of theory) of the title compound.
[0266] LC-MS (Method A): R.sub.t=1.19 min; MS(ESIpos): m/z=653.3
[M+H].sup.+
[0267] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.23-7.54 (m,
7H), 6.88 (d, 1H), 5.75 (s, 1H), 5.22-4.96 (m, 2H), 4.28 (d, 1H),
4.08-3.72 (m, 2H), 1.78 (br. s., 3H), 1.51 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(1S)-1-
-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hyd-
roxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-8)
##STR00052##
[0269] A mixture of 129 mg (0.2 mmol) of the compound from step a)
and 200 .mu.l (0.2 mmol) of 1 M sodium hydroxide solution in 1.2 ml
of methanol was stirred at 0.degree. C. for 2 min and at RT for 90
min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400 mesh)
was added and the mixture was stirred at RT for 30 min. The ion
exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 109 mg (90% of theory) of the title
compound.
[0270] LC-MS (Method A): R.sub.t=1.08 min; MS(ESIpos): m/z=611.0
[M+H].sup.+
[0271] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.15-7.92 (m,
2H), 7.82-7.56 (m, 5H), 6.89 (d, 1H), 5.51 (d, 1H), 5.18-4.96 (m,
2H), 4.64 (t, 1H), 4.29 (d, 1H), 4.10-3.73 (m, 2H), 1.37 (d,
3H)
Example 15
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-chloro-4-(trifluorom-
ethoxy)phenyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-9)
[0272] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 1.5 ml of THF. After 30 min at 0.degree. C., 107
mg (0.44 mmol) of 2-chloro-4-(trifluoromethoxy)phenylhydrazine
(XIII) were added and then the mixture was stirred at RT overnight.
The reaction mixture was then heated in the microwave at
100.degree. C. for 3 h. A few drops of water were added to the
reaction mixture, which was purified by chromatography (preparative
HPLC, eluent: acetonitrile/water gradient, 0.1% formic acid).
Lyophilization of the product-containing fractions gave 152 mg (57%
of theory) of the title compound.
[0273] LC-MS (Method A): R.sub.t=1.23 min; MS(ESIpos): m/z=669.1
[M+H].sup.+
[0274] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.01-7.53 (m,
7H), 6.89 (d, 1H), 5.92-5.60 (m, 1H), 5.11 (d, 2H), 4.39-4.19 (m,
1H), 4.09-3.77 (m, 2H), 1.77 (br. s., 3H), 1.54 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[2-chloro-4-(trifluoromethoxy)phenyl]-5-[(1S)--
1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hy-
droxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-9)
##STR00053##
[0276] A mixture of 141 mg (0.21 mmol) of the compound from step a)
and 210 .mu.l (0.21 mmol) of 1 M sodium hydroxide solution in 1.3
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 125 mg (94% of theory) of the title
compound.
[0277] LC-MS (Method A): R.sub.t=1.11 min; MS(ESIpos): m/z=627.3
[M+H].sup.+
[0278] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.87 (d, 1H),
7.82-7.71 (m, 4H), 7.67-7.51 (m, 4H), 6.89 (d, 1H), 5.54 (d, 1H),
5.07 (d, 2H), 4.75-4.58 (m, 1H), 4.39-4.17 (m, 1H), 4.08-3.74 (m,
2H), 1.40 (d, 3H)
Example 16
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2,6-dichlorophenyl]-1H-
-1,2,4-triazol-5-yl}ethyl Acetate (XIV-A-10)
[0279] While cooling with ice, 73 .mu.l (0.58 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 200 mg (0.53 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 276 .mu.l (1.58
mmol) of DIPEA in 2 ml of THF. After 1 h at 0.degree. C., 124 mg
(0.58 mmol) of 2,6-dichlorophenylhydrazine (XIII) hydrochloride
were added and then the mixture was stirred at RT overnight. The
reaction mixture was then heated in the microwave at 100.degree. C.
for 3 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 124 mg (37% of theory) of the
title compound.
[0280] LC-MS (Method A): R.sub.t=1.08 min; MS(ESIpos): m/z=619.0
[M+H].sup.+
[0281] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.84-7.52 (m,
1H), 6.89 (d, 1H), 5.78 (d, 1H), 5.13 (d, 2H), 4.41-4.20 (m, 1H),
4.11-3.70 (m, 2H), 1.78 (s, 3H), 1.55 (d, 3H)
b)
5-(4-Chlorophenyl)-2-(({1-(2,6-dichlorophenyl)-5-[(1S)-1-hydroxyethyl]--
1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-
-dihydro-3H-1,2,4-triazol-3-one (I-A-10)
##STR00054##
[0283] A mixture of 119 mg (0.19 mmol) of the compound from step a)
and 190 .mu.l (0.19 mmol) of 1 M aqueous sodium hydroxide solution
in 2 ml of methanol was stirred at 0.degree. C. for 2 min and at RT
for 90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 110 mg (quant.) of the title compound.
[0284] LC-MS (Method A): R.sub.t=1.00 min; MS(ESIpos): m/z=576.9
[M+H].sup.+
[0285] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.81-7.54 (m,
7H), 6.90 (d, 1H), 5.55 (d, 1H), 5.19-4.96 (m, 2H), 4.63 (t, 1H),
4.30 (d, 1H), 4.08-3.77 (m, 2H), 1.41 (d, 3H)
Example 17
a)
(1R)-1-[3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(2,6-dichlorophenyl)-1H-
-1,2,4-triazol-5-yl]ethyl Acetate (XIV-B-10)
[0286] While cooling with ice, 73 .mu.l (0.58 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 200 mg (0.53 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 276 .mu.l (1.58
mmol) of DIPEA in 2 ml of THF. After 30 min at 0.degree. C., 124 mg
(0.58 mmol) of 2,6-dichlorophenylhydrazine (XIII) hydrochloride
were added and then the mixture was stirred at RT overnight. The
reaction mixture was then heated in the microwave at 150.degree. C.
for 3 h. A few drops of water were added to the reaction mixture,
which was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 151 mg (46% of theory) of the
title compound.
[0287] LC-MS (Method A): R.sub.t=1.12 min; MS(ESIpos): m/z=619.2
[M+H].sup.+
[0288] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.83-7.56 (m,
8H), 6.90 (d, 1H), 5.78 (d, 1H), 5.13 (d, 2H), 4.42-4.12 (m, 1H),
4.06-3.74 (m, 2H), 1.78 (s, 3H), 1.55 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-(2,6-dichlorophenyl)-5-[(1R)-1-hydroxyethyl]-1-
H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4--
dihydro-3H-1,2,4-triazol-3-one (I-B-10)
##STR00055##
[0290] A mixture of 141 mg (0.23 mmol) of the compound from step a)
and 230 .mu.l (0.23 mmol) of 1 M sodium hydroxide solution in 2.4
ml of methanol was stirred at 0.degree. C. for 2 min and at RT for
90 min. 0.5 g of activated ion exchanger (Dowex 50WX8, 200-400
mesh) was added and the mixture was stirred at RT for 30 min. The
ion exchanger was then filtered off, and washed with methanol. The
filtrate was concentrated and the residue was dried under reduced
pressure. This gave 128 mg (97% of theory) of the title
compound.
[0291] LC-MS (Method A): R.sub.t=1.01 min; MS(ESIpos): m/z=577.2
[M+H].sup.+
[0292] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.78-7.57 (m,
7H), 6.90 (d, 1H), 5.55 (d, 1H), 5.08 (d, 2H), 4.63 (t, 1H),
4.40-4.19 (m, 1H), 4.12-3.76 (m, 2H), 1.41 (d, 3H)
Example 18
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethoxy)ph-
enyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-11)
[0293] While cooling with ice, 55 .mu.l (0.44 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 150 mg (0.40 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 207 .mu.l (1.19
mmol) of DIPEA in 3 ml of THF. After 30 min at 0.degree. C., 143 mg
(0.73 mmol) of 2-trifluoromethoxyphenylhydrazine (XIII)
hydrochloride were added and then the mixture was stirred at RT
overnight. The reaction mixture was subsequently heated in the
microwave at 120.degree. C. for 3 h and purified by chromatography
(preparative HPLC, eluent: acetonitrile/water gradient, 0.1% formic
acid). Lyophilization of the product-containing fractions gave 141
mg (56% of theory) of the title compound.
[0294] LC-MS (Method A): R.sub.t=1.14 min; MS(ESIpos): m/z=635.3
[M+H].sup.+
b)
5-(4-Chlorophenyl)-2-({5-[(1S)-1-hydroxyethyl]-1-[2-(trifluoromethoxy)p-
henyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxyprop-
yl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-11)
##STR00056##
[0296] A mixture of 140 mg (0.22 mmol) of the compound from step a)
and 220 .mu.l (0.22 mmol) of 1 M sodium hydroxide solution in 2 ml
of methanol was stirred at RT for 60 min. Subsequently, 17 .mu.l of
50% formic acid were added and the mixture was purified by
chromatography (preparative HPLC, eluent: acetonitrile/water
gradient, 0.1% formic acid). Lyophilization of the
product-containing fractions gave 123 mg (94% of theory) of the
title compound.
[0297] LC-MS (Method A): R.sub.t=1.04 min; MS(ESIpos): m/z=593.3
[M+H]+
[0298] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.77-7.51 (m,
8H), 6.89 (d, 1H), 5.54 (d, 1H), 5.06 (d, 2H), 4.63 (t, 1H),
4.41-4.18 (m, 1H), 4.07-3.77 (m, 2H), 1.40 (d, 3H)
Example 19
a)
(1R)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethoxy)ph-
enyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-B-11)
[0299] While cooling with ice, 109 mg (0.73 mmol) of
(R)-(-)-2-acetoxypropionyl chloride (XII-B) were added dropwise to
a mixture of 250 mg (0.66 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 345 .mu.l (1.98
mmol) of DIPEA in 5 ml of THF. After 30 min at 0.degree. C., 166 mg
(0.73 mmol) of 2-trifluoromethoxyphenylhydrazine (XIII)
hydrochloride were added and then the mixture was stirred at RT
overnight. The reaction mixture was subsequently heated in the
microwave at 120.degree. C. for 3 h and purified by chromatography
(preparative HPLC, eluent: acetonitrile/water gradient, 0.1% formic
acid). Lyophilization of the product-containing fractions gave 167
mg (39% of theory) of the title compound.
[0300] LC-MS (Method A): R.sub.t=1.13 min; MS(ESIpos): m/z=635.3
[M+H].sup.+
[0301] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.83-7.48 (m,
8H), 6.89 (d, 1H), 5.75 (d, 1H), 5.10 (d, 2H), 4.41-4.20 (m, 1H),
4.11-3.76 (m, 2H), 1.75 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({5-[(1R)-1-hydroxyethyl]-1-[2-(trifluoromethoxy)p-
henyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxyprop-
yl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-B-11)
##STR00057##
[0303] A mixture of 158 mg (0.25 mmol) of the compound from step a)
and 250 .mu.l (0.25 mmol) of 1 M sodium hydroxide solution in 3 ml
of methanol was stirred at 0.degree. C. for 2 min and at RT for 90
min. Subsequently, 19 .mu.l of 50% formic acid were added and the
mixture was purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid).
[0304] Lyophilization of the product-containing fractions gave 139
mg (94% of theory) of the title compound.
[0305] LC-MS (Method A): R.sub.t=1.00 min; MS(ESIpos): m/z=593.00
[M+H].sup.+
[0306] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.80-7.51 (m,
8H), 6.90 (d, 1H), 5.54 (d, 1H), 5.06 (s, 2H), 4.63 (t, 1H),
4.39-4.21 (m, 1H), 4.08-3.76 (m, 1H), 1.40 (d, 1H)
Example 20
a)
(1S)-1-[1-(2,6-Difluorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3-
,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-
-1,2,4-triazol-5-yl]ethyl Acetate (XIV-A-12)
[0307] While cooling with ice, 37 .mu.l (0.29 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 100 mg (0.26 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 138 .mu.l (0.79
mmol) of DIPEA in 2 ml of THF. After 30 min at 0.degree. C., 53 mg
(0.29 mmol) of 2,6-difluorophenylhydrazine (XIII) were added and
then the mixture was stirred at RT overnight. The reaction mixture
was subsequently heated in the microwave at 120.degree. C. for 3 h
and purified by chromatography (preparative HPLC, eluent:
acetonitrile/water gradient, 0.1% formic acid). Lyophilization of
the product-containing fractions gave 130 mg (83% of theory) of the
title compound.
[0308] LC-MS (Method A): R.sub.t=1.07 min; MS(ESIpos): m/z=587.1
[M+H].sup.+
[0309] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.91-7.31 (m,
7H), 6.89 (d, 1H), 5.74 (d, 1H), 5.12 (d, 2H), 4.40-4.18 (m, 1H),
4.09-3.74 (m, 2H), 1.80 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-(2,6-difluorophenyl)-5-[(1S)-1-hydroxyethyl]-1-
H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4--
dihydro-3H-1,2,4-triazol-3-one (I-A-12)
##STR00058##
[0311] A mixture of 120 mg (0.20 mmol) of the compound from step a)
and 200 .mu.l (0.20 mmol) of 1 M sodium hydroxide solution in 2 ml
of methanol was stirred at RT for 60 min. Subsequently, 16 .mu.l of
50% formic acid were added and the mixture was purified by
chromatography (preparative HPLC, eluent: acetonitrile/water
gradient, 0.1% formic acid). Lyophilization of the
product-containing fractions gave 110 mg (99% of theory) of the
title compound.
[0312] LC-MS (Method A): R.sub.t=0.97 min; MS(ESIpos): m/z=545.2
[M+H].sup.+
[0313] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.86-7.57 (m,
5H), 7.38 (s, 2H), 6.89 (d, 1H), 5.63 (d, 1H), 5.08 (s, 2H), 4.74
(t, 1H), 4.30 (d, 1H), 4.11-3.71 (m, 2H), 1.39 (d, 3H)
Example 21
a)
(1S)-1-{3-({3-(4-Chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxyp-
ropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[4-chloro-2-(trifluorom-
ethoxy)phenyl]-1H-1,2,4-triazol-5-yl}ethyl acetate (XIV-A-13)
[0314] While cooling with ice, 37 .mu.l (0.29 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 100 mg (0.26 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 138 .mu.l (0.79
mmol) of DIPEA in 2 ml of THF. After 30 min at 0.degree. C., 53 mg
(0.29 mmol) of 4-chloro-2-(trifluoromethoxy)phenylhydrazine were
added and then the mixture was stirred at RT overnight. The
reaction mixture was subsequently heated in the microwave at
120.degree. C. for 3 h and purified by chromatography (preparative
HPLC, eluent: acetonitrile/water gradient, 0.1% formic acid).
Lyophilization of the product-containing fractions gave 76 mg (43%
of theory) of the title compound.
[0315] LC-MS (Method A): R.sub.t=1.17 min; MS(ESIpos): m/z=669.1
[M+H].sup.+
[0316] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=8.01-7.53 (m,
7H), 6.88 (d, 1H), 5.74 (d, 1H), 5.10 (d, 2H), 4.29 (d, 1H),
4.10-3.75 (m, 2H), 1.79 (s, 3H), 1.53 (d, 3H)
b)
5-(4-Chlorophenyl)-2-({1-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[(1S)--
1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hy-
droxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (I-A-13)
##STR00059##
[0318] A mixture of 70 mg (0.10 mmol) of the compound from step a)
and 105 .mu.l (0.10 mmol) of 1 M sodium hydroxide solution in 1 ml
of methanol was stirred at RT for 30 min. Subsequently, 8 .mu.l of
50% formic acid were added and the mixture was purified by
chromatography (preparative HPLC, eluent: acetonitrile/water
gradient, 0.1% formic acid). Lyophilization of the
product-containing fractions gave 59 mg (90% of theory) of the
title compound.
[0319] LC-MS (Method A): R.sub.t=1.12 min; MS(ESIpos): m/z=627.3
[M+H].sup.+
[0320] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.87-7.56 (m,
7H), 6.92-6.85 (m, 1H), 5.55 (d, 1H), 5.20-4.96 (m, 2H), 4.68 (t,
1H), 4.29 (d, 1H), 4.10-3.73 (m, 1H), 1.40 (d, 1H)
Example 22
a)
(1S)-1-[1-(2-Chlorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-t-
rifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-1,2-
,4-triazol-5-yl]ethyl Acetate (XIV-A-14)
[0321] While cooling with ice, 5.2 ml (41.0 mmol) of
(S)-(-)-2-acetoxypropionyl chloride (XII-A) were added dropwise to
a mixture of 14.1 g (37.3 mmol) of methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 32.5 ml (41.0
mmol) of DIPEA in 303 ml of THF. After 1.5 h at 0.degree. C., 7.35
mg (0.44 mmol) of 2-chlorophenylhydrazine (XIII) hydrochloride were
added and the mixture was stirred at RT for 1.5 h. The reaction
mixture was then heated in the microwave at 100.degree. C. for 10
h. The reaction mixture was then admixed with water and ethyl
acetate and stirred vigorously. The phases were separated. The
aqueous phase was extracted with ethyl acetate. The organic phase
was washed with saturated aqueous ammonium chloride solution, dried
over magnesium sulphate and concentrated under reduced pressure.
The residue was purified by chromatography (silica gel, eluent:
cyclohexane/ethyl acetate gradient). Concentration of the
product-containing fractions by rotary evaporation gave 10.4 mg
(47% of theory) of the title compound.
[0322] LC-MS (Method A): R.sub.t=1.09 min; MS(ESIpos): m/z=585.2
[M+H].sup.+
[0323] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.84-7.49 (m,
8H), 6.89 (d, 1H), 5.75 (br. s, 1H), 5.22-5.00 (m, 2H), 4.4-3.70
(m, 3H), 1.77 (br s, 3H), 1.58-1.44 (m, 3H)
b)
2-({1-(2-Chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}me-
thyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihy-
dro-3H-1,2,4-triazol-3-one (I-A-14)
##STR00060##
[0325] A mixture of 10.4 g (17.7 mmol) of the compound from step a)
and 2.84 g (35.5 mmol) of a 50% aqueous sodium hydroxide solution
in 110 ml of methanol/water mixture (10:1) was stirred at 0.degree.
C. for 2 min and at RT for 1 h. The mixture was added to water and
adjusted to pH 7 with a 1 N hydrochloric acid solution. The aqueous
phase was extracted with MTBE. The organic phase was washed with
saturated aqueous sodium chloride solution, dried over magnesium
sulphate and concentrated under reduced pressure. This gave 10.6 g
(quant.) of the title compound.
[0326] LC-MS (Method 2): R.sub.t=1.75 min; MS(ESIpos): m/z=543.1
[M+H].sup.+
[0327] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.94-7.35 (m,
8H), 6.89 (d, 1H), 5.50 (d, 1H), 5.07 (d, 2H), 4.69-3.70 (m, 4H),
1.38 (d, 3H)
Example 23
a)
(1R)-1-[1-(2-Chlorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2R)-3,3,3-t-
rifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-1,2-
,4-triazol-5-yl]ethyl Acetate (XIV-B-14)
[0328] 1.09 g (7.3 mmol) of (R)-(-)-2-acetoxypropionyl chloride
(XII-B) were added dropwise to a mixture of 2.5 g (6.6 mmol) of
methyl
2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5--
dihydro-1H-1,2,4-triazol-1-yl}ethanimidate (XI) and 4.6 ml (26.4
mmol) of DIPEA in 65 ml of dioxane. After 30 min at RT, 1.3 g (7.3
mmol) of 2-chlorophenylhydrazine (XIII) were added. The reaction
mixture was stirred at RT for 2 h and heated under reflux
overnight. The reaction mixture was concentrated and purified by
chromatography (silica gel, eluent: cyclohexane/ethyl acetate
gradient). Concentration of the product-containing fractions by
rotary evaporation gave 2.87 g (74% of theory) of the title
compound.
[0329] LC-MS (Method A): R.sub.t=1.12 min; MS(ESIpos): m/z=585.2
[M+H].sup.+
[0330] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.90-7.45 (m,
8H), 6.89 (d, 1H), 5.86-5.53 (m, 1H), 5.11 (d, 2H), 4.37-4.22 (m,
1H), 4.11-3.78 (m, 2H), 1.77 (br s, 3H), 1.53 (d, 3H)
b)
2-({1-(2-Chlorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}me-
thyl)-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihy-
dro-3H-1,2,4-triazol-3-one (I-B-14)
##STR00061##
[0332] A mixture of 2.94 g (5.0 mmol) of the compound from step a)
and 30 mg (0.27 mmol) of caesium carbonate in 52 ml of methanol was
stirred at RT overnight. The reaction mixture was concentrated. The
residue was dissolved with ethyl acetate, and washed with 1 N
hydrochloric acid solution and then with saturated aqueous sodium
chloride solution. The organic phase was dried over magnesium
sulphate and concentrated under reduced pressure. This gave 2.63 g
(96% of theory) of the title compound.
[0333] LC-MS (Method 1): R.sub.t=0.94 min; MS(ESIpos): m/z=543.0
[M+H].sup.+
[0334] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.=7.93-7.42 (m,
8H), 6.90 (d, 1H), 5.50 (br d, 1H), 5.07 (s, 2H), 4.59 (br s, 1H),
4.30 (br d, 1H), 4.13-3.76 (m, 2H), 1.38 (d, 3H)
[0335] Measuring Parameters of the x-Ray Diffractometry for the
Analysis of the Compound of the Formula (I) in Crystalline Form of
Polymorph I:
TABLE-US-00001 Scan axis gonio Start position [.degree.2.theta.]
2.0066 End position [.degree.2.theta.] 37.9906 Measurement
temperature [.degree. C.] 25 Anode material Cu K-alpha1 [.ANG.]
1.54060 K-a1pha2 [.ANG.] 1.54443 K-beta [.ANG.] 1.39225 K-alpha
2/K-alpha 1 0.50000 Generator setting 40 mA, 40 kV Incident beam
monochromator focusing x-ray mirror Sample rotation yes
TABLE-US-00002 TABLE 1 Peak maxima of the 2 theta angle Peak
maximum [2 theta] Polymorph I 5.6 7.0 7.5 8.9 9.4 10.6 10.8 13.3
14.4 14.7 15.1 15.5 16.8 17.0 17.7 17.9 18.1 18.4 18.8 19.3 20.3
20.9 21.1 21.2 21.6 21.8 22.1 22.4 23.0 23.2 23.4 23.7 24.0 24.1
24.6 25.0 26.1 27.1
DESCRIPTION OF THE FIGURES
[0336] The FIGURE illustrates X-ray diffractogram of the compound
of the formula (I-A-1) in crystalline form of polymorph I.
* * * * *
References